

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Clinical Correlates of Antidepressant Use in a Secondary Mental Health Care Setting

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-022170 |
| Article Type: | Research |
| Date Submitted by the Author: | 18-Mar-2018 |
| Complete List of Authors: | Fernandes, Andrea; Institute of Psychiatry, Psychology and Neuroscience, Biomedical Research Centre Nucleu Chandran, David; Institute of Psychiatry, Psychology and Neuroscience, Biomedical Research Centre Nucleu Khondoker, Mizanur; University of East Anglia, Medical Statistics Dewey, Michael; Kings College, Institute of Psychiatry, Health Service and Population Research Dept Shetty, Hitesh; South London and Maudsley NHS Foundation Trust, Biomedical Research Centre Nucleus Dutta, Rina; Kings College London, Institute of Psychiatry, Psychology and Neuroscience Stewart, Robert; King's College London, Institute of Psychiatry |
| Keywords: | antidepressant use, antidepressant prescription, clinical factors, psychiatric service, secondary care, depressive disorders |
| | |

SCHOLARONE™
Manuscripts

Only

Clinical Correlates of Antidepressant Use in a Secondary Mental Health Care Setting

Andrea C Fernandes¹, David Chandran², Mizanur Khondokar³, Michael Dewey⁴, Hitesh Shetty², Rina Dutta²,

Robert Stewart²

¹ Psychological Medicine, King's College London (KCL), Institute of Psychiatry, Psychology and Neuroscience

² Biomedical Research Centre Nucleus, South London and Maudsley NHS Foundation Trust

³ Medical Statistics, University of East Anglia

⁴ Freelance Health statistics consultant and KCL Emeritus Professor of Statistics in Epidemiology

Correspondence to Andrea C. Fernandes: andrea.fernandes@kcl.ac.uk

Abstract

Objective: To investigate the association between clinical correlates and antidepressant use in a psychiatric healthcare setting using a retrospective cohort study design.

Setting: Data was extracted from an interactive database sourced from a secondary psychiatric electronic register based in South East London. Relative risk ratio estimates were obtained from multinomial logistic regression analysis to ascertain the probability of receiving common antidepressant treatments relative to Sertraline.

Participants: Patients were included if they received active care (defined as at least one face-to-face contact with the service) and a clinical diagnosis of depression with antidepressant treatment between 1st March 2015 and 31st August 2015. Patients were excluded if they did not receive any antidepressants or received a combination of three or more antidepressants.

Results: Age was associated with increased use of all antidepressants, except for Fluoxetine (RRR 0.98; 95% CI 0.96 – 0.98) and a combination of two SSRIs (0.98; 0.96 – 0.99). Male gender was associated with increased use of mirtazapine compared to female patients (2.57; 1.85 – 3.57). Past antidepressant use, past antipsychotic and mood stabiliser use were associated with newer antidepressant use (i.e. SNRIs, mirtazapine or a combination of both). Affective symptoms were associated with reduced use of citalopram (0.58; 0.27 – 0.83) and fluoxetine (0.42; 0.22 – 0.72) and somatic symptoms were associated with increased use of mirtazapine (1.60; 1.00 – 2.75) relative to sertraline. Furthermore, in adults, past benzodiazepine use was associated with a combination of SSRIs (2.97; 1.32 – 6.68), mirtazapine (1.94; 1.20 – 3.16) and venlafaxine (1.87; 1.04 – 3.34), whilst past suicide attempts were associated with increased use of fluoxetine (2.06; 1.10 – 3.87) relative to sertraline.

Conclusion: There were some associations of patient and clinical correlates with antidepressant treatment use, which contributes towards understanding the association of antidepressants with suicidality.

Keywords: antidepressant use; depressive disorders; secondary care; psychiatric service; clinical factors; antidepressant prescription

Strengths and Limitations of this study

- This is the first study profiling antidepressant use in a cohort of treatment resistant patients receiving treatment in a secondary mental health care setting in the UK.
- The data included hard to measure variables such as depressive symptoms owing to the use of text mining algorithms.
- Using antidepressant data in a 6-month window limited sample sizes included in analysis hence while trends were detected in univariate analysis (past medication use, past symptom experience) they disappeared in the fully adjusted analysis.
- The study is cross-sectional and any significant results do not indicate any direct causal relationship.
- The duration of the antidepressant treatment during the observation period was not known and this could hinder interpretation of the results given some patients were new users of the antidepressants, while others could be using the antidepressants for longer periods of time.

Introduction

There are standard national guidelines directing antidepressant prescription in secondary care¹; however in practice a range of patient and clinician characteristics may influence this^{1,2} because those seen by secondary services are a select group, skewed towards patients with treatment-resistant moderate to severe disorders³. Studies profiling antidepressant prescription in secondary care can highlight factors that play a key role in managing treatment-resistant depression and individuals with exacerbated symptom profiles. British guidelines for the management of depression in secondary care specify that care plans should involve, among other things, the development of a crisis plan that identifies and details management of potential triggers for a depressive episode or a worsening of existing symptoms¹. Knowledge of factors involved in antidepressant prescription can provide a pragmatic idea of how antidepressants are being prescribed, how this reflects existing guidelines and can help inform policy and practice.

Studies to date profiling antidepressant prescriptions have established that patient-clinician relationships, past experiences and patient symptoms can influence antidepressant prescription; however, these have been set in primary care⁴⁻⁷ and there are few studies investigating factors associated with antidepressant use in a secondary mental healthcare setting^{8,9}. To the best of our knowledge there has not been a study profiling antidepressant prescription in the UK, outside of primary care^{10,11}. The objective of our study was to investigate which clinical symptoms (including previous suicide attempts), past treatment and demographic factors are associated with different antidepressant treatment schedules in a mental healthcare setting.

Methods

The Dataset

The Clinical Record Interactive Search (CRIS) system provides de-identified case note information from the South London and Maudsley (SLaM) NHS Trust, a large mental healthcare provider serving a geographic catchment of approximately 1.3 million residents in four south London boroughs (Lambeth, Southwark, Lewisham, and Croydon). Electronic health records (EHRs) have been used comprehensively across all SLaM services since 2006. CRIS was established in 2008 to allow searching and retrieval of de-identified¹² clinical information for research purposes within a robust, patient-led governance framework, and currently houses records on over 250,000 cases^{13,14}. The system allows for retrieval of information from de-identified structured and free-text fields, and the use of CRIS for research was approved by the Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). Patient consent was not required due to research data being pseudonymised.

Observation Window and Inclusion Criteria

A 6-month interval from 1st March to 31st August 2015 was selected as the observation period where type of antidepressant use, defined as single antidepressant use and antidepressants users on two antidepressants (referred to here as binary antidepressant use) represented the main dependent variable. All antidepressant use groups were mutually exclusive as described in the next section. Independent variables (demographic and clinical variables) were extracted 12 months prior to the observation window and their associations with antidepressant use within the observation window were analysed.

Patients were included if they received active SLaM care between 1st March 2015 and 31st August 2015, and had received any of the following clinical diagnoses according to 10th Revision of the International Classification of Diseases (ICD-10) codes on or before the 31st of August 2015: Depressive episode (F32), Recurrent depressive disorder (F33), Dysthymia (F34.1), and/or Mixed Anxiety and Depression (F41.2). Individuals were excluded if they had received any F01 – F09 (Dementia and Alzheimer's), F20 – F29 (Schizophrenia and Schizoaffective disorders) or F31 (bipolar disorders) diagnoses on or before the 31st of August 2015. Active care was defined as at least one face-to-face contact with SLaM service within the observation window. Patients were excluded if they did not receive any antidepressants during the window or if they received a combination of three or more antidepressants during this window.

Antidepressant Use

Antidepressant use data was ascertained using text mining software, GATE and TextHunter,¹⁵ designed to extract data specifically on any medication recorded in free-text fields (e.g. case notes, correspondence). Details of the development of this algorithm have previously been published^{14,16}. For each patient in the final cohort, any antidepressant use (regardless of the stage of antidepressant use) during the observation window was extracted as a binary variable. The antidepressants for which data were collected comprised the following: i) tricyclic and tricyclic related - amitriptyline, clomipramine, dosulepin, doxepin, imipramine, lofepramine, nortriptyline, trimipramine, mianserin and trazodone; ii) mono-amine oxidase inhibitors (MAOIs) - isocarboxazid, phenelzine, tranylcypromaine and moclobemide; iii) Selective Serotonin Re-uptake Inhibitors (SSRIs) - sertraline, fluoxetine, citalopram, escitalopram, fluvoxamine and paroxetine; iv) Selective Norepinephrine Reuptake Inhibitors (SNRIs) - venlafaxine, reboxetine and duloxetine; and v) Other classes - agomelatine, bupropion, and mirtazapine.

The final cohort comprised 1,561 patients. The most common mutually exclusive monotherapy antidepressant used within the 6-month window was sertraline (360 patients), followed by mirtazapine (305), citalopram (213), fluoxetine (200), venlafaxine (143), escitalopram (52). The most common mutually exclusive double antidepressant combinations were any one SSRI with mirtazapine (110), any one SNRI with mirtazapine (89) and a combination of any two SSRIs (89). Groups with less than 50 patients or with more than two antidepressants being used in combination were excluded from the analysis to avoid low sample sizes and inaccurate representation of antidepressant use. All antidepressant groups were mutually exclusive.

Clinical Determinants included in the Study

Apart from demographic variables, all other covariate data was extracted from data recorded in the 12 months prior to the observation window. Demographic variables were recorded in structured fields, but all other data variables (listed below) were individually extracted using GATE and TextHunter, two text mining software tools which can be programmed to extract data from free-text notes via rules-based and machine learning techniques, respectively. All clinical symptom data variables were extracted using TextHunter. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the same period.

1
2
3 **Demographic variables:** Ethnicity, age, gender, marital status and area-level deprivation score; latest
4 diagnostic code (this served as a proxy indicator of severity of depression); **Past medication/therapy use:** Non-
5 antidepressant medication data: antipsychotic, benzodiazepine, mood stabilizer and antidepressant use in the
6 past 12 months; **Patient Referral data:** Length of current referral and having been an inpatient in the past 12
7 months; **Non-medication therapies:** Psychotherapy in the past 12 months and referral to IAPT services.
8
9
10
11 **Clinical symptom data collected were Past psychotic symptoms:** Hallucinations and delusions; **Patients'**
12 **past depressive symptoms:** 14 symptoms of depression were extracted from TextHunter. To avoid small
13 patient groups for analysis, depressive symptoms were clustered together. Deciding which symptoms to cluster
14 together was based on results from a study using confirmatory factor analysis on the Beck Depressive
15 Inventory-II (Beck et al, 1996) using an at risk (clinical) psychiatric population¹⁷. There is evidence for
16 grouping the Beck Inventory items into three factors: Somatic, Affective and Cognitive. Studies have supported
17 these findings^{18,19} or generated two different factors in older populations²⁰. Hence the groupings are as follows:
18
19 **Cognitive symptoms:** helplessness, worthlessness and hopelessness; **Affective symptoms:** anhedonia, poor
20 motivation, apathy and low mood; **Somatic symptoms:** poor concentration, agitation, irritability, low energy,
21 insomnia, poor appetite and anergia. **Suicidal behaviour:** suicidal ideation, suicide attempt in the past 12
22 months.
23
24
25
26
27
28
29
30
31
32

33 **Statistical Analysis**

34
35 Group differences were analysed using Chi-squared tests for categorical variables and t-tests or one-
36 way ANOVAs for normally distributed continuous variables, or the Kruskal-Wallis test for non-normally
37 distributed continuous data. Multinomial logistic regression analyses were used to answer the research question.
38 The probability of receiving any of the common antidepressant treatments relative to sertraline (the referent
39 antidepressant class, since it consisted of the most patient users) was estimated using exponentiated regression
40 coefficients from the multinomial regression which represents Relative Risk Ratios (RRR). In order to build a
41 representative model of which correlates predict antidepressant use in secondary care, decisions to include
42 variables in the final model were guided by the contribution of each variable in an initial model including age
43 and gender as covariates. Variables that did not have any significant associations in age- and gender- adjusted
44 analysis were not included in the final model. For initial selection based on age- and gender- adjusted analysis,
45 the significance was set at $p \leq 0.25$ ²¹. This was to help minimise i) exclusion of potentially key covariates and
46 ii) inclusion of $p < 0.05$ significant estimates occurring by chance. The selected variables were then
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 simultaneously entered in a full model. In the fully adjusted model significance level was set at $p < 0.05$ for
4 retaining variables. The correlates retained in the final multinomial regression model were age, gender, past
5 inpatient status, past benzodiazepine use, past antipsychotic use, past mood stabiliser use, past antidepressant
6 use, past psychotherapy and IAPT referrals, past experience of psychotic, somatic, affective and cognitive
7 symptoms; and past experience of suicidal ideation and past suicide attempts. In addition, separate analysis was
8 conducted in the adult group only (i.e. 26 years or older) because most of the patient cohort consisted of adults
9 (See Cohort demographics in Table 1) and different factors may need to be taken into consideration when
10 considering prescriptions of antidepressants to children, adolescents and young people relative to adults^{1,22}.
11
12
13
14
15
16
17

18 **Results**

19 Table 1 compares each antidepressant or antidepressant combination by demographics, referral data,
20 past medication use and past psychological therapy referral. The demographic and clinical differences between
21 the antidepressant groups are statistically significant apart from ethnicity, area deprivation and having had a past
22 referral for psychotherapy. Notably, a majority of young patients receive fluoxetine, whilst the older patients are
23 on a combination of newer antidepressants such as mirtazapine and a SNRI; there are more males receiving
24 mirtazapine than females; most of the antidepressant users are single, and only a minority have had non-
25 antidepressant treatment or psychotherapy in the past. Table 2 indicates that the majority of patients have a
26 moderate to severe diagnosis of depression, a large majority of whom have not experienced suicidal ideation or
27 attempted suicide. Apart from severity and past psychotic symptoms, for all other past depressive symptoms and
28 past suicidal ideation and attempts, the analysis indicated significant heterogeneity across the antidepressant
29 user groups. Tables 3 and 4 show the Relative Risk Ratio (RRR), estimating the probability of patients being on
30 any antidepressant relative to sertraline (the most common antidepressant received in our cohort), derived from
31 the fully adjusted multinomial logistic regression models in the entire cohort and the adult-only cohort
32 respectively.
33
34
35
36
37
38
39
40
41
42
43

44 Table 3 shows that relative to females, males are more likely to be on mirtazapine relative to sertraline.
45 It also indicates that patients on newer antidepressants are more likely to have used non-antidepressant
46 medication or been on antidepressants in the past. Those on citalopram or fluoxetine are less likely to have
47 experienced affective symptoms (such as low mood and poor motivation) in the past compared to those on
48 sertraline, whilst those who have experienced somatic symptoms (such as insomnia and agitation) in the past are
49 more likely to be on mirtazapine relative to sertraline.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The results from the adult-only analysis (Table 4) again show increased likelihood of males being on
4 mirtazapine compared to females. They also show that relative to sertraline, patients on citalopram or fluoxetine
5 are less like to have experienced severe affective symptoms. Patients on mirtazapine are more likely to have
6 experienced somatic symptoms relative to sertraline compared to those who experienced milder symptoms. Of
7
8 note, in the adult-only analysis patients on fluoxetine were more likely to have made at least one suicide attempt
9
10 in the past 12 months relative to those on sertraline.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The aim of this study was to ascertain patient demographic and clinical characteristics that correlate with antidepressant use in patients actively receiving secondary health care for clinical depression. While there were no notable trends that suggested definite demographics, medication or depressive clinical symptoms may be associated with antidepressant use, our results suggest that in adults age, gender, past medication use and having made suicide attempts in the past 12 months are some of the factors that could contribute to antidepressant use in secondary care.

We found that with every unit increase in age, patients are less likely to be using fluoxetine or a combination of two SSRIs relative to sertraline. Comparable to our study, a large scale study using a cohort of war veterans with a diagnosis of depression (Veterans' Affairs [VA] dataset; N = 507,179)⁹ to investigate whether patient and clinical variables were predictors of newly initiated antidepressant use, found that relative to younger patients, older patients were less likely (RRR 0.70; 95% CI: 0.67- 0.73) to have started on fluoxetine than sertraline. We also found that men, compared to women, are more likely to use mirtazapine relative to sertraline. Mirtazapine has been shown to have lower incidence of sexual dysfunction side-effects²³ and may be more likely to be prescribed to men.

Our results also suggest that, in adults, past suicide attempts were associated with increased likelihood of using fluoxetine relative to sertraline, which may reflect the evidence collated from meta-analyses of randomized controlled trials and observation studies where fluoxetine has been shown to carry reduced risk of suicidal behaviour in adults compared to children and adolescents²⁴⁻²⁶. There are indications in our analysis that patients on past non-antidepressant and antidepressant medication are more likely to be on newer antidepressants such as mirtazapine and venlafaxine or a combination of low toxicity antidepressants. As this cohort may predominantly consist of individuals' with some resistance to first line antidepressant treatment, it may follow that these individuals were on other medication in the past and have now been switched to newer antidepressants.

The lack of notable trend of covariates associated with antidepressant use potentially suggests that antidepressants may be prescribed based on individual experiences after patient-clinician communication, which supports the advice set by the British guidelines emphasising patient-clinician communication. However, the current study only provides speculative indication and further qualitative studies may be able to confirm this.

The results have to be interpreted with study limitations in mind. Firstly, using antidepressant data in a 6-month window limited sample sizes included in analysis. So while trends were detected in univariate analysis

1
2
3 (past medication use, past symptom experience) they disappeared in the fully adjusted analysis. Secondly, the
4 study is cross-sectional and any significant results do not indicate any direct causal relationship. Thirdly, the
5 duration of the antidepressant treatment during the observation period was not known and this could hinder
6 interpretation of the results given some patients were new users of the antidepressants, while others could be
7 using the antidepressants for longer periods of time. The results of the study may not be generalizable to patients
8 in other secondary psychiatric healthcare settings due to the potential ethnic diversity found in south east
9 London where this study is based. Finally, we could only investigate factors that were available to us in the
10 current dataset. The literature reports various clinical covariates⁸, patient demographics⁹, medication use²⁷,
11 clinician characteristics²⁸ and clinical location^{8,9} as factors involved for antidepressant prescription in secondary
12 mental healthcare settings. We could not account for all these factors in our analysis.
13
14
15
16
17
18
19
20

21 Limitations notwithstanding there are key strengths to this paper. To our knowledge this is the first
22 study profiling antidepressant use in a cohort of treatment resistant patients receiving treatment in a secondary
23 mental health care setting in the UK. In addition, the data included hard to measure variables such as depressive
24 symptoms owing to the use of text mining algorithms which allows for capture of data recorded in free-text and
25 circumvented the need to use data from structured fields.
26
27
28
29

30 The individual significant findings could inform clinical practice within this clinical setting.
31 Knowledge of factors involved in antidepressant prescription could be used to audit clinical practices and
32 inform whether the clinical practices are benefitting patient treatment outcomes²⁹. Further qualitative work
33 could highlight main themes involved in selecting antidepressant treatment. Continual monitoring of treatment
34 choices in this cohort may contribute to providing optimal care for secondary care patients.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Acknowledgements:* The authors of this work thank MD for initial advice and guidance on the statistical
4 analysis, and extend sincere gratitude to MK for his patient and continuous support on statistical analysis.

5
6 *Contributors:* RS, RD and AF conceived of the study and were responsible for the design and search strategy.
7
8 AF, HS and DC were responsible for data extraction. AF was responsible for conducting the analysis and
9
10 producing the tables. The analysis was guided by MD initially and then MK. The initial draft of the manuscript
11
12 was prepared by AF then circulated among all authors for revision. All authors helped to evolve analysis plans,
13
14 interpret data and critically revise successive drafts of the manuscript.

15 *Funding:* This research received no specific grant from any funding agency in the public, commercial or not-
16
17 for-profit sectors.

18 *Competing interests:* None.

19
20 *Provenance and peer review:* Not commissioned; externally peer reviewed.

21
22 *Data sharing statement:* No additional data available. The use of CRIS for research was approved by the
23
24 Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). Patient consent was not required due to
25
26 research data being pseudonymised.

27
28 *Statement on manuscript:* The lead author (the manuscript's guarantor) affirms that the manuscript is an honest,
29
30 accurate, and transparent account of the study being reported; that no important aspects of the study have been
31
32 omitted; and that any discrepancies from the study as planned have been explained.

References

- 1 National Institute for Health & Clinical Excellence (NICE) Guideline. National Clinical Practice Guideline 90: Depression The NICE Guidelines on the Treatment and Management of Depression in Adults - The Updated Edition. The British Psychological Society and The Royal College of Psychiatrists, 2010.
- 2 Zetin M, Hoepner CT, Bjornson L. Rational Antidepressant Selection: Applying Evidence-Based Medicine to Complex Real-World Patients. *Evid Based Med* 2006; **39**: 38–104.
- 3 Huxley P, Goldberg D. Mental health in the community: the pathways to psychiatric care. *London Tavistock Publ* 1980.
- 4 Meijer WEE, Heerdink ER, Leufken HGM, Herings MC, Egberts ACG, Nolen WA. Incidence and determinants of long-term use of antidepressants. *Eur J Clin Pharmacol* 2004; **60**: 57–61.
- 5 Sleath B, Shih YCT. Sociological influences on antidepressant prescribing. *Soc Sci Med* 2003; **56**: 1335–44.
- 6 Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, *et al*. Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study. *Eur Psychiatry* 2008; **23**: 66–73.
- 7 Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. *Ann Pharmacother* 2000; **34**: 10–4.
- 8 Kim HM, Zivin K, Choe HM, Stano CM, Ganoczy D, Walters H, *et al*. Predictors of Start of Different Antidepressants in Patient Charts among Patients with Depression. *J Manag Care Spec Pharm* 2015; **21**: 424–30.
- 9 Kim HM, Zivin K, Ganoczy D, Pfeiffer P, Hoggatt K, McCarthy JF, *et al*. Predictors of alternative antidepressant agent initiation among U.S. veterans diagnosed with depression. *Pharmacoepidemiol Drug Saf* 2010; **19**: 1049–56.
- 10 Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, *et al*. Influences on antidepressant prescribing trends in the UK: 1995–2011. *Soc Psychiatry Psychiatr Epidemiol* 2017; **52**: 193–200.
- 11 Shi N, Durden E, Torres A, Cao Z, Happich M. Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom. *Depress Res Treat* 2012; **2012**.
- 12 Fernandes AC, Cloete D, Broadbent MTM, Hayes RD, Chang C, Jackson RG, *et al*. Development and

- 1
2
3 evaluation of a de-identification procedure for a case register sourced from mental health electronic
4 records. *BMC Med Inform Decis Mak* 2013; **13**: 1–14.
5
- 6 13 Stewart R, Soremekun M, Perera G, Broadbent M, Callard F, Denis M, *et al*. The South London and
7 Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register:
8 development and descriptive data. *BMC Psychiatry* 2009; **9**: 51.
9
- 10 14 Perera G, Broadbent M, Callard F, Chang C, Downs J, Dutta R, *et al*. Cohort profile of the South
11 London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case
12 Register : current status and recent enhancement of an Electronic Mental Health Record-derived data
13 resource. *BMJ Open* 2016; **6**: e008721.
14
- 15 15 Cunningham H, Maynard D, Bontcheva K, Tablan V, Aswani N, Roberts I, *et al*. *Text Processing with*
16 *GATE (Version 6)*. University of Sheffield Department of Computer Science, 2011.
17
- 18 16 Jackson RG, Ball M, Patel R, Hayes RD, Dobson RJB, Stewart R. TextHunter – A User Friendly Tool
19 for Extracting Generic Concepts from Free Text in Clinical Research. *Proc Am Med Informatics Assoc*
20 2014; **2014**: 729–38.
21
- 22 17 Arnarson P, Olason D, Smari J, Sigurdsson JF. The Beck Depression Inventory Second Edition student
23 and patient populations The Beck Depression Inventory Second Edition (BDI-II): Psychometric
24 properties in Icelandic student and patient populations. *Nord J Psychiatry* 2009; **62**: 360–5.
25
- 26 18 Ward LC. Comparison of Factor Structure Models for the Beck Depression Inventory — II. *Psychol*
27 *Assess* 2006; **18**: 81–8.
28
- 29 19 Subica AM, Fowler JC, Elhai JD, Frueh BC, Sharp C, Kelly EL, *et al*. Factor Structure and Diagnostic
30 Validity of the Beck Depression Inventory-II With Adult Clinical Inpatients: Comparison to a Gold-
31 Standard Diagnostic Interview. *Psychol Assess* 2014; **26**: No-Specified.
32
- 33 20 Prince MJ, Reischies F, Beekman AT, Fuhrer R, Jonker C, Kivela SL, *et al*. Development of the EURO-
34 D scale--a European, Union initiative to compare symptoms of depression in 14 European centres. *Br J*
35 *Psychiatry* 1999; **174**: 330–8.
36
- 37 21 Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic
38 regression. *Source Code Biol Med* 2008; **3**: 17.
39
- 40 22 Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, *et al*. Evidence-based guidelines
41 for treating depressive disorders with antidepressants: A revision of the 2000 British Association for
42 Psychopharmacology guidelines. *J Psychopharmacol* 2015; **29**: 459–524.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 23 Saiz-Ruiz J, Montes J, Ibanez A, Diaz M, Vicente F, Pelegrin C, *et al.* Assessment of Sexual
4 Functioning in Depressed Patients Treated With Mirtazapine: A Naturalistic 6-Month Study. *Hum*
5 *Psychopharmacol Clin Exp* 2005; **6**: 435–40.
6
7
8 24 Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a
9 systematic review of observational studies. *CMAJ* 2009; **3**: 291–7.
10
11 25 Gibbons RD, Brown CH, Hur K, Davis J, Mann J. Suicidal thoughts and behavior with antidepressant
12 treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Arch*
13 *Gen Psychiatry* 2012; **69**: 580–7.
14
15 26 Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin
17 reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
18 *Lancet* 2004; **363**: 1341–5.
19
20 27 Sirey JA, Meyers BS, Bruce ML, Alexopoulos GS, Perlick DA, Raue P. Predictors of Antidepressant
21 Prescription and Early Use Among Depressed Outpatients. *Am J Psychiatry* 1999; **156**: 690–6.
22
23 28 Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, *et al.* Which Factors
24 Influence Psychiatrists' Selection of Antidepressants? *Am J Psychiatry* 2004; **161**: 1285–9.
25
26 29 Lin SY, Stevens MB. The Symptom Cluster-Based Approach to Individualize Patient-Centered
27 Treatment for Major Depression. *J Am Board Fam Med* 2014; **27**: 151–9.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Demographics, Patient Referral data, Past Medication use and Past Psychological Therapy characteristics by Common Antidepressant User Groups

| | Any one SNRI and Mirtazapine (89) | Any one SSRI and Mirtazapine (110) | Any two SSRIs (89) | Citalopram (213) | Escitalopram (52) | Fluoxetine (200) | Mirtazapine (305) | Sertraline (360) | Venlafaxine (143) | Total 1561 | Test statistic; p-value _{c,d} |
|--|-----------------------------------|------------------------------------|--------------------|------------------|-------------------|------------------|-------------------|------------------|-------------------|------------|--|
| DEMOGRAPHICS | | | | | | | | | | | |
| Mean Age in years [SD] | 52.9 [16.6] | 48.6 [18.6] | 34.1 [16.2] | 42.7 [15.5] | 44.1 [16.3] | 33.3 [16.0] | 49.2 [18.8] | 39.3 [16.8] | 48.8 [18.1] | 1561 | 25.38; <0.001 |
| Gender: Female | 60 (67.4%) | 65 (59.6) | 64 (71.9) | 147 (69) | 35 (67.3) | 139 (69.5) | 138 (45.2) | 251 (69.7) | 91 (63.6) | 990 | 60.07; <0.001 |
| Male | 29 (32.6%) | 44 (40.4) | 25 (28.1) | 66 (31) | 17 (32.70) | 61 (30.5) | 167 (54.8) | 109 (30.3) | 52 (36.4) | 571 | |
| Ethnicity: White | 61 (68.5%) | 69 (62.7) | 49 (55.1) | 135 (63.4) | 39 (75) | 127 (63.5) | 176 (57.7) | 213 (59.2) | 101 (70.6) | 970 | 15.70; 0.05 |
| Other | 28 (31.5%) | 41 (37.3) | 40 (44.9) | 78 (36.6) | 13 (25) | 73 (36.5) | 129 (42.3) | 147 (40.8) | 42 (29.4) | 591 | |
| Marital Status: Single | 34 (38.2%) | 61 (55.5) | 47 (52.8) | 127 (59.6) | 25 (48.1) | 133 (66.5) | 169 (55.4) | 216 (60) | 79 (55.2) | 891 | df= 16; 37.40; 0.002 |
| Married | 31 (34.8%) | 26 (23.6) | 24 (27.0) | 40 (18.8) | 18 (34.6) | 23 (11.5) | 72 (23.6) | 80 (22.2) | 35 (24.5) | 349 | |
| Other | 24 (27%) | 23 (20.9) | 18 (20.2) | 46 (21.6) | 9 (17.3) | 44 (22) | 64 (21) | 64 (17.8) | 29 (20.3) | 321 | |
| ^a 1 st Tertile (2.25 – 22.3) | 29 (32.6%) | 27 (25.5) | 31 (34.8) | 62 (29.5) | 20 (38.5) | 64 (32.3) | 82 (27.2) | 122 (34.5) | 60 (42.9) | 497 | df= 16; 26.33; 0.05 |
| ² nd Tertile | 50 (56.2%) | 67 (63.2) | 44 (49.4) | 131 (62.4) | 26 (50) | 120 (60.6) | 184 (60.9) | 205 (57.9) | 71 (50.7) | 898 | |
| ³ rd Tertile (42.3 – 62.3) | 10 (11.2%) | 12 (11.3) | 14 (15.7) | 17 (8.1) | 6 (11.5) | 14 (7.1) | 36 (11.9) | 27 (7.6) | 9 (6.4) | 145 | |
| REFERRAL DATA | | | | | | | | | | | |
| Length of Spell: Mean years (SD) | 0.91 [2.45] | 0.94 [1.94] | 0.51 [0.77] | 0.80 [2.80] | 1.04 [1.50] | 0.81 [1.16] | 0.90 [1.64] | 0.73 [1.27] | 1.40 [3.00] | | 2.00; 0.043 |
| Past ^b Inpatient at SLaM: Yes | 16 (18%) | 24 (21.8) | 16 (18) | 18 (8.5) | 3 (5.8) | 13 (6.5) | 32 (10.5) | 47 (13.1) | 16 (11.2) | 185 | 27.64 <0.001 |
| No | 73 (82%) | 86 (78.2) | 73 (82) | 195 (91.5) | 49 (94.2) | 187 (93.5) | 273 (89.5) | 313 (86.9) | 127 (88.8) | 1376 | |
| PAST^b MEDICATION USE | | | | | | | | | | | |
| Benzodiazepine Use: Yes | 26 (29.2%) | 25 (22.7) | 19 (21.4) | 35 (16.4) | 11 (21.2) | 21 (10.5) | 71 (23.3) | 55 (15.3) | 36 (25.2) | 299 | 28.01 <0.001 |
| No | 63 (70.8%) | 85 (77.3) | 70 (78.6) | 178 (83.6) | 41 (78.8) | 179 (89.5) | 234 (76.7) | 305 (84.7) | 107 (74.8) | 1262 | |
| Antipsychotic Use: Yes | 39 (43.8%) | 35 (31.8) | 22 (24.7) | 46 (21.6) | 18 (34.6) | 41 (20.5) | 97 (31.8) | 92 (25.6) | 53 (37.1) | 443 | 32.07; <0.001 |
| No | 50 (56.2%) | 75 (68.2) | 67 (75.3) | 167 (78.4) | 34 (65.4) | 159 (79.5) | 208 (68.2) | 268 (74.4) | 90 (62.9) | 1118 | |
| Mood Stabiliser Use: Yes | 13 (14.6%) | 7 (6.4) | 5 (5.6) | 8 (3.8) | 6 (11.5) | 10 (5) | 19 (6.2) | 15 (4.2) | 21 (14.7) | 104 | 33.48 <0.001 |
| No | 76 (85.4%) | 103 (93.6) | 84 (94.4) | 205 (96.2) | 46 (88.4) | 190 (95) | 286 (93.8) | 345 (95.8) | 122 (85.3) | 1457 | |
| Antidepressant Use: Yes | 82 (92.1%) | 86 (78.2) | 61 (68.5) | 132 (62) | 41 (78.8) | 150 (75) | 233 (76.4) | 273 (75.8) | 114 (79.7) | 1172 | 38.43; <0.001 |
| No | 7 (7.9%) | 24 (21.8) | 28 (31.5) | 81 (38) | 11 (21.2) | 50 (25) | 72 (23.6) | 87 (24.2) | 29 (20.3) | 389 | |
| PAST^b PSYCHOLOGICAL THERAPY REFERRAL | | | | | | | | | | | |
| Psychotherapy Referral: Yes | 13 (14.6%) | 18 (16.4) | 11 (12.4) | 14 (6.6) | 7 (13.5) | 22 (11) | 29 (9.5) | 46 (12.8) | 19 (13.3) | 179 | 11.03 0.200 |
| No | 76 (85.4%) | 92 (83.6) | 78 (87.6) | 199 (93.4) | 45 (86.5) | 178 (89) | 276 (90.5) | 314 (87.2) | 124 (86.7) | 1382 | |
| IAPT Referral: Yes | 51 (57.3%) | 50 (45.5) | 40 (44.9) | 108 (50.7) | 27 (51.9) | 77 (38.5) | 131 (42.9) | 181 (50.3) | 58 (40.6) | 723 | 17.21 0.028 |
| No | 38 (42.7%) | 60 (54.5) | 49 (55.1) | 105 (49.3) | 25 (48.1) | 123 (61.5) | 174 (57.1) | 179 (49.7) | 85 (59.4) | 838 | |

a – Area-level Deprivation Tertiles (1st Tertile: Least Deprived; 3rd Tertile: Most Deprived); b – “Past” refers to the 12 months prior to the observation window. ; Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period; c –ANOVA, Chi-square test, t-tests or the Kruskal-Wallis tests were conducted to test differences between patient groups; d - degree of freedom (df) = 8, unless otherwise specified.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2: Depression Severity and Past Clinical Symptoms Groups by Common Antidepressant User Groups

| | Any one SNRI and Mirtazapine (89) | Any one SSRI and Mirtazapine (110) | Any two SSRIs (89) | Citalopram (213) | Escitalopram (52) | Fluoxetine (200) | Mirtazapine (305) | Sertraline (360) | Venlafaxine (143) | Total (1561) | Test statistic; p-value ^{c,d} |
|----------------------------------|-----------------------------------|------------------------------------|--------------------|------------------|-------------------|------------------|-------------------|------------------|-------------------|--------------|--|
| DEPRESSION SEVERITY | | | | | | | | | | | |
| Depression Severity: Mild | 16 (18) | 22 (20) | 19 (21.4) | 33 (15.5) | 14 (26.9) | 41 (20.5) | 57 (18.7) | 79 (21.9) | 22 (15.4) | 303 | df = 16; 17.44 |
| Moderate to Severe | 49 (55) | 50 (45.5) | 37 (41.6) | 91 (42.7) | 18 (34.6) | 84 (42) | 185 (60.7) | 165 (45.8) | 60 (42) | 739 | |
| Other | 13 (14.6) | 13 (11.8) | 15 (16.9) | 45 (21.1) | 9 (17.3) | 29 (14.5) | 52 (17.1) | 59 (16.4) | 34 (23.8) | 269 | |
| PAST SYMPTOMS^b | | | | | | | | | | | |
| Past Psychotic Symptoms: | | | | | | | | | | | |
| Zero to One mention | 68 (76.4) | 77 (70) | 70 (78.7) | 176 (82.6) | 46 (88.5) | 168 (84) | 238 (78.1) | 293 (81.4) | 112 (78.3) | 1248 | 14.33; 0.073 |
| >= 2 mentions | 21 (23.6) | 33 (30) | 19 (21.3) | 37 (17.4) | 6 (11.5) | 32 (16) | 67 (21.9) | 67 (18.6) | 31 (21.7) | 313 | |
| Past Cognitive Symptoms: | | | | | | | | | | | |
| Zero to One mention | 62 (69.7) | 78 (70.9) | 68 (76.4) | 186 (87.3) | 45 (86.5) | 179 (89.5) | 254 (83.3) | 293 (81.4) | 111 (77.6) | 1276 | 34.50; <0.001 |
| >= 2 mentions | 27 (30.3) | 32 (29.1) | 21 (23.6) | 27 (12.6) | 7 (13.5) | 21 (10.5) | 51 (16.7) | 67 (18.6) | 32 (22.4) | 285 | |
| Past Affective Symptoms: | | | | | | | | | | | |
| Zero to One mention | 29 (32.6) | 40 (36.4) | 33 (37.1) | 119 (55.9) | 24 (46.2) | 110 (55) | 113 (37.1) | 131 (36.4) | 52 (36.4) | 651 | 46.24 <0.001 |
| >= 2 mentions | 60 (67.4) | 70 (63.6) | 56 (62.9) | 94 (44.1) | 28 (53.8) | 90 (45) | 192 (62.9) | 229 (63.6) | 91 (63.6) | 910 | |
| Past Somatic Symptoms: | | | | | | | | | | | |
| Zero to One mention | 39 (43.8) | 57 (51.2) | 49 (55.1) | 154 (72.3) | 34 (65.4) | 134 (67) | 155 (50.8) | 203 (56.4) | 85 (59.4) | 900 | 42.07; <0.001 |
| >= 2 mentions | 50 (56.2) | 53 (48.1) | 40 (44.9) | 59 (27.7) | 18 (34.6) | 66 (33) | 150 (49.2) | 157 (43.6) | 58 (40.6) | 651 | |
| PAST SUICIDALITY | | | | | | | | | | | |
| Past Suicide Ideation: Yes | | | | | | | | | | | |
| Yes | 33 (37.1) | 38 (34.5) | 30 (33.7) | 40 (18.8) | 10 (19.2) | 44 (22) | 78 (25.6) | 101 (28.1) | 35 (24.5) | 409 | 22.12; <0.05 |
| No | 56 (62.9) | 72 (65.5) | 59 (66.3) | 173 (81.2) | 42 (80.8) | 156 (78) | 227 (74.4) | 259 (71.9) | 108 (75.5) | 1152 | |
| Past Suicide Attempt: Yes | | | | | | | | | | | |
| Yes | 20 (22.4) | 34 (30.9) | 30 (33.7) | 39 (18.3) | 6 (11.5) | 48 (24) | 65 (21.3) | 77 (21.4) | 32 (22.4) | 351 | 17.37; <0.05 |
| No | 69 (77.5) | 76 (69.1) | 59 (66.3) | 174 (81.7) | 46 (88.5) | 152 (76) | 240 (76.7) | 283 (78.6) | 111 (77.6) | 1210 | |

b – “Past” refers to the 12 months prior to the observation window; Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period

c –ANOVA, Chi-square test, t-tests or the Kruskal-Wallis tests were conducted to test differences between patient groups;

d - degree of freedom (df) = 8, unless otherwise specified.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 3: Fully adjusted Relative Risk Ratio estimates from Multinomial Logistic Regression models with sertraline as the Referent Group in the Entire Cohort (N = 1561)

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|--|---------------------------------------|--|--|--------------------|---------------------------------------|--|--|
| Age | 1.05 (1.03 – 1.04)[‡] | 1.03 (1.02 – 1.04)[‡] | 0.98 (0.96 – 0.99)^{**} | 1.01 (1.00 – 1.02)^{**} | 1.01 (0.99 – 1.03) | 0.98(0.96 – 0.98)[‡] | 1.03 (1.02 – 1.04)[‡] | 1.03 (1.02 – 1.03)[‡] |
| Gender (a) | 0.97 (0.57 – 1.76) | 1.33 (0.84 – 2.09) | 0.95 (0.56 – 1.61) | 0.95 (0.65 – 1.39) | 1.07 (0.56 – 2.01) | 1.08 (0.73 – 1.60) | 2.57 (1.85 – 3.57)[‡] | 1.16 (0.76 – 1.76) |
| Past Inpatient: Yes (b) | 1.09 (0.47 – 1.54) | 1.26 (0.59 – 2.70) | 0.97 (0.42 – 2.27) | 0.80 (0.43 – 1.88) | 0.60 (0.14 – 2.60) | 0.48 (0.21 – 1.07) | 0.68 (0.37 – 1.27) | 0.70 (0.32 – 1.54) |
| Past Benzodiazepine Use: Yes (b) | 1.30 (0.70 – 2.81) | 1.03 (0.55 – 1.90) | 1.63 (0.82 – 3.25) | 1.60 (0.94 – 2.73) | 1.77 (0.78 – 4.01) | 0.97 (0.53 -1.77) | 1.58 (1.00 – 2.50) | 1.63 (0.94 – 2.81) |
| Past Antipsychotic Use: Yes (b) | 1.78 (1.03 – 2.36)^{**} | 1.17 (0.69 – 1.99) | 0.91 (0.49 – 1.70) | 0.99 (0.63 – 1.60) | 1.53 (0.77 – 3.07) | 0.74 (0.46 – 1.17) | 1.19 (0.80 – 1.75) | 1.47 (0.91 – 2.36) |
| Past Mood Stabiliser Use: Yes (b) | 2.38 (1.04 – 6.34)^{**} | 1.23 (0.47 – 3.20) | 1.50 (0.50 – 4.36) | 0.99 (0.40 – 2.42) | 2.60 (0.93 – 7.27) | 1.65 (0.71 - 3.86) | 1.23 (0.60 – 2.55) | 2.96 (1.44 – 6.08)^{**} |
| Past Antidepressant Use: Yes (b) | 3.06 (1.34 – 7.85)^{**} | 0.95 (0.50 – 1.78) | 0.59 (0.31 – 1.10) | 0.76 (0.48 – 1.20) | 1.27 (0.55 – 2.94) | 1.42 (0.88 – 2.30) | 0.98 (0.63 – 1.53) | 1.10 (0.62 – 1.96) |
| Has had Psychotherapy treatment before: Yes (b) | 0.67 (0.31 – 1.51) | 0.91 (0.45 – 1.75) | 0.88 (0.42 – 1.86) | 0.51 (0.27 – 0.98)^{**} | 1.17 (0.48 – 2.89) | 0.91 (0.51 – 1.64) | 0.55 (0.32 – 0.94)^{**} | 0.81 (0.43 – 1.52) |
| Has been referred to IAPT services: Yes (b) | 1.90 (1.15 – 1.91)^{**} | 1.02 (0.65 – 1.60) | 0.81 (0.50 – 1.33) | 0.96 (0.68 – 1.37) | 1.18 (0.64 – 2.17) | 0.62 (0.43 - 0.91)[‡] | 0.88 (0.63 – 1.22) | 0.79 (0.53 – 1.20) |
| Psychotic Symptom:>2 mentions (c) | 0.82 (0.38 – 1.89) | 1.54 (0.72 – 2.71) | 1.00 (0.58 – 2.12) | 1.53 (0.95 – 3.00) | 0.67 (0.26 – 2.26) | 1.42 (0.79 – 2.51) | 1.16 (0.64 – 1.73) | 1.17 (0.54 – 1.90) |
| Cognitive Symptom:>2 mentions (c) | 1.37 (0.67 – 2.67) | 1.40 (0.72 – 2.76) | 1.18 (0.56 – 2.47) | 0.94 (0.54 – 1.87) | 0.96 (0.30 – 2.17) | 0.77 (0.39 – 1.44) | 0.72 (0.49 – 1.38) | 1.32 (0.76 – 2.67) |
| Affective Symptom: >2 mentions (c) | 0.53 (0.28 – 1.31) | 0.60 (0.24 – 1.13) | 0.93 (0.33 – 1.66) | 0.58 (0.27 – 0.83)^{**} | 0.72 (0.31 – 1.87) | 0.42 (0.22 – 0.72)[‡] | 0.79 (0.41 – 1.18) | 0.92 (0.36 – 1.32) |
| Somatic Symptom: >2 mentions (c) | 1.40 (0.63 – 1.78) | 1.02 (0.65 – 2.84) | 0.92 (0.47 – 2.33) | 0.65 (0.36 – 1.16) | 0.84 (0.39 – 2.40) | 1.10 (0.62 – 1.97) | 1.60 (1.00 – 2.75)^{**} | 0.70 (0.50 – 1.80) |
| Past Suicide Ideation: Yes (b) | 1.34 (0.76 – 1.33) | 1.07 (0.62 – 1.86) | 1.04 (0.57 – 1.90) | 0.80 (0.50 – 1.29) | 0.75 (0.34 – 1.68) | 0.88 (0.55 – 1.42) | 0.90 (0.60 – 1.36) | 0.79 (0.47 – 1.33) |
| Past Suicide Attempt: Yes (b) | 1.01 (0.51 – 2.05) | 1.49 (0.82 – 2.68) | 1.74 (0.95 – 3.19) | 1.23 (0.74 – 2.05) | 0.66 (0.25 – 1.74) | 1.57 (0.97 – 2.54) | 1.13 (0.72 – 1.77) | 1.18 (0.67 – 2.06) |

p-value: ‡ <0.05; †† < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

Table 4: Fully adjusted Relative Risk Ratio estimates from Multinomial Logistic Regression models with sertraline as the Referent Group in the adult-only sample (N = 1248)

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|--|---------------------------------------|--|--|--------------------|--|--|--|
| Age | 1.04 (1.02 – 1.05)[‡] | 1.03 (1.01 – 1.04)[‡] | 0.99 (0.97 – 1.01) | 1.00 (0.99 – 1.02) | 1.00 (0.98 – 1.03) | 0.99 (0.98 – 1.01) | 1.03 (1.02 – 1.04)[‡] | 1.02 (1.01 – 1.04)[‡] |
| Gender (a) | 0.87 (0.51 – 1.50) | 1.29 (0.79 – 2.11) | 0.89 (0.47 – 1.69) | 0.89 (0.59 – 1.35) | 1.04 (0.52 – 2.07) | 1.25 (0.78 – 2.00) | 2.36 (1.64 – 3.37)[‡] | 1.10 (0.70 – 1.73) |
| Past Inpatient: Yes (b) | 1.10 (0.45 – 2.69) | 0.96 (0.40 – 2.24) | 0.30 (0.07 – 1.26) | 0.83 (0.36 – 1.95) | 0.50 (0.09 – 3.23) | 0.50 (0.18 – 1.37) | 0.62 (0.31 – 1.24) | 0.61 (0.25 – 1.47) |
| Past Benzodiazepine Use: Yes (b) | 1.46 (0.76 – 2.78) | 1.25 (0.65 – 2.41) | 2.97 (1.32 – 6.68)^{**} | 1.61 (0.89 – 2.90) | 1.90 (0.80 – 4.49) | 1.13 (0.57 – 2.24) | 1.94 (1.20 – 3.16)^{**} | 1.87 (1.04 – 3.34)^{**} |
| Past Antipsychotic Use: Yes (b) | 2.02 (1.14 – 3.58)^{**} | 1.30 (0.73 – 2.32) | 1.02 (0.46 – 2.26) | 1.08 (0.66 – 1.80) | 1.55 (0.73 – 3.30) | 1.02 (0.57 – 1.80) | 1.16 (0.76 – 1.78) | 1.53 (0.92 – 2.57) |
| Past Mood Stabiliser Use: Yes (b) | 2.26 (0.97 – 5.30) | 1.03 (0.37 – 2.90) | 1.17 (0.31 – 4.44) | 0.78 (0.30 – 2.14) | 2.67 (0.91 – 7.76) | 1.75 (0.68 – 4.47) | 1.27 (0.60 – 2.71) | 2.76 (1.28 – 5.97)^{**} |
| Past Antidepressant Use: Yes (b) | 2.70 (1.07 – 6.86)^{**} | 0.81 (0.41 – 1.61) | 0.44 (0.20 – 0.95)^{**} | 0.72 (0.43 – 1.21) | 2.07 (0.43 – 5.54) | 1.07 (0.20 – 1.96) | 0.83 (0.50 – 1.36) | 1.09 (0.60 – 2.05) |
| Has had Psychotherapy treatment before: Yes (b) | 0.80 (0.36 – 1.76) | 1.30 (0.64 – 2.63) | 0.95 (0.33 – 2.71) | 0.52 (0.24 – 1.15) | 1.75 (0.66 – 4.57) | 1.12 (0.51 – 2.44) | 0.68 (0.38 – 1.23) | 0.86 (0.43 – 1.73) |
| Has been referred to IAPT services: Yes (b) | 2.04 (1.20 – 3.48)^{**} | 0.99 (0.60 – 1.62) | 0.93 (0.50 – 1.73) | 1.00 (0.67 – 1.50) | 1.36 (0.70 – 2.66) | 0.98 (0.61 – 1.68) | 0.93 (0.64 – 1.34) | 0.83 (0.53 – 1.31) |
| Psychotic Symptom: >2 mentions (c) | 0.81 (0.39 – 1.69) | 1.67 (0.85 – 3.26) | 0.88 (0.36 – 2.22) | 1.70 (0.94 – 3.09) | 0.70 (0.23 – 2.13) | 1.45 (0.75 – 2.81) | 1.24 (0.75 – 2.06) | 1.19 (0.63 – 2.23) |
| Cognitive Symptom: >2 mentions (c) | 1.16 (0.58 – 2.34) | 1.26 (0.63 – 2.53) | 0.88 (0.35 – 2.26) | 0.86 (0.44 – 1.66) | 0.98 (0.33 – 2.88) | 0.77 (0.37 – 1.64) | 0.61 (0.36 – 1.05) | 1.12 (0.58 – 2.13) |
| Affective Symptom: >2 mentions (c) | 0.51 (0.25 – 1.03) | 0.57 (0.29 – 1.12) | 0.93 (0.41 – 2.10) | 0.51 (0.30 – 0.86)^{**} | 0.48 (0.21 – 1.10) | 0.35 (0.19 – 0.66)^{**} | 0.82 (0.50 – 1.32) | 0.95 (0.53 – 1.68) |
| Somatic Symptom: >2 mentions (c) | 1.39 (0.71 – 2.74) | 1.01 (0.52 – 1.96) | 1.11 (0.49 – 2.48) | 0.66 (0.38 – 1.14) | 1.02 (0.47 – 2.42) | 1.18 (0.63 – 2.19) | 1.61 (1.01 – 2.56)^{**} | 0.70 (0.39 – 1.22) |
| Past Suicide Ideation: Yes (b) | 1.37 (0.75 – 2.50) | 1.03 (0.57 – 1.89) | 0.89 (0.40 – 1.98) | 0.80 (0.47 – 1.37) | 0.50 (0.19 – 1.34) | 0.92 (0.51 – 1.67) | 0.93 (0.59 – 1.46) | 0.84 (0.48 – 1.48) |
| Past Suicide Attempt: Yes (b) | 1.04 (0.51 – 2.11) | 1.51 (0.78 – 2.91) | 1.74 (0.76 – 4.00) | 1.35 (0.75 – 2.41) | 0.44 (0.12 – 1.64) | 2.06 (1.10 – 3.87)^{**} | 1.18 (0.71 – 1.95) | 1.19 (0.63 – 2.20) |

p-value: [‡] <0.05; ^{**} < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

| | Item No. | STROBE items | Location in manuscript where items are reported | RECORD items | Location in manuscript where items are reported |
|---------------------------|----------|--|---|---|---|
| Title and abstract | | | | | |
| | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 2 | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | Page 2 |
| Introduction | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 4 | | |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 4 | | |
| Methods | | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | Page 2 | | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 5, 6 and 7 | | |
| Participants | 6 | (a) <i>Cohort study</i> - Give the eligibility criteria, and the | Page 5 | RECORD 6.1: The methods of study population selection (such as codes or | Page 5 - 8 |

| | | | | | | |
|---|------------------------------|---|--|--|---|------------|
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 | | <p>sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p> | | <p>algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p> | | |
| 25 26 27 28 29 30 31 | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Page 5- 8 | RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | Page 5 - 8 |
| 32 33 34 35 36 37 38 39 | Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 5 – 8 | | |
| 40 41 42 | Bias | 9 | Describe any efforts to address potential sources of bias | Page 5 | | |
| 43 44 45 46 47 | Study size | 10 | Explain how the study size was | Page 5 | | |

| | | | | |
|---|----------------------------------|------------|--|--|
| | | arrived at | | |
| 1 2 3 4 5 6 | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | |
| 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses | Page 7 |
| 31 32 33 34 35 36 37 38 39 40 41 | Data access and cleaning methods | | .. | RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. |
| 42 43 44 | Linkage | | .. | RECORD 12.3: State whether the study included person-level, institutional- |
| | | | | Page 5 |
| | | | | Page 5 |

| | | | | | |
|------------------|----|---|-----------------|--|--------|
| | | | | level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided. | |
| Results | | | | | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram | Page 8 | RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram. | Page 5 |
| Descriptive data | 14 | (a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount) | Page 8, 16 - 21 | | |
| Outcome data | 15 | <i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures | Page 16 - 21 | | |
| Main results | 16 | (a) Give unadjusted estimates | Page 16 - 21 | | |

| | | | | | |
|-------------------|----|---|---------|--|---------|
| | | and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | | | |
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Page 8 | | |
| Discussion | | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Page 10 | | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 10 | RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported. | Page 10 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Page 10 | | |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 11 | | |

| Other Information | | | | |
|---|----|---|---------|---|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 12 | |
| Accessibility of protocol, raw data, and programming code | | .. | | RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code. Not Applicable |

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

BMJ Open

Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-022170.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 28-May-2018 |
| Complete List of Authors: | Fernandes, Andrea; Institute of Psychiatry, Psychology and Neuroscience, Biomedical Research Centre Nucleu Chandran, David; Institute of Psychiatry, Psychology and Neuroscience, Biomedical Research Centre Nucleu Khondoker, Mizanur; University of East Anglia, Medical Statistics Dewey, Michael; Kings College, Institute of Psychiatry, Health Service and Population Research Dept Shetty, Hitesh; South London and Maudsley NHS Foundation Trust, Biomedical Research Centre Nucleus Dutta, Rina; Kings College London, Institute of Psychiatry, Psychology and Neuroscience Stewart, Robert; King's College London, Institute of Psychiatry |
| Primary Subject Heading: | Mental health |
| Secondary Subject Heading: | Mental health, Epidemiology |
| Keywords: | antidepressant use, antidepressant prescription, clinical factors, psychiatric service, secondary care, depressive disorders |
| | |

SCHOLARONE™
Manuscripts

Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting

Andrea C Fernandes¹, David Chandran^{1,2}, Mizanur Khondokar³, Michael Dewey⁴, Hitesh Shetty², Rina Dutta^{1,2},
Robert Stewart^{1,2}

¹ King's College London (KCL), Institute of Psychiatry, Psychology and Neuroscience, London, UK

² South London and Maudsley NHS Foundation Trust, London, UK

³ Medical Statistics, University of East Anglia

⁴ Freelance Health statistics consultant and KCL Emeritus Professor of Statistics in Epidemiology

Correspondence to Andrea C. Fernandes: andrea.fernandes@kcl.ac.uk

Abstract

Objective: To investigate the demographic and clinical factors associated with antidepressant use for depressive disorder in a psychiatric healthcare setting using a retrospective cohort study design.

Setting: Data were extracted from a de-identified data resource sourced from the electronic health records of a London mental health service. Relative risk ratios were obtained from multinomial logistic regression analysis to ascertain the probability of receiving common antidepressant treatments relative to sertraline.

Participants: Patients were included if they received mental health care and a diagnosis of depression with antidepressant treatment between March and August 2015 and exposures were measured over the preceding 12 months.

Results: Older age was associated with increased use of all antidepressants compared to sertraline, except for negative associations with fluoxetine (Relative Risk Ratio [RRR] 0.98; 95%CI 0.96-0.98) and a combination of two SSRIs (0.98; 0.96-0.99), and no significant association with escitalopram. Male gender was associated with increased use of mirtazapine compared to sertraline (2.57; 1.85-3.57). Previous antidepressant, antipsychotic and mood stabiliser use were associated with newer antidepressant use (i.e. SNRIs, mirtazapine or a combination of both), while affective symptoms were associated with reduced use of citalopram (0.58; 0.27-0.83) and fluoxetine (0.42; 0.22-0.72) and somatic symptoms were associated with increased use of mirtazapine (1.60; 1.00-2.75) relative to sertraline. In patients older than 25 years, past benzodiazepine use was associated with a combination of SSRIs (2.97; 1.32-6.68), mirtazapine (1.94; 1.20-3.16) and venlafaxine (1.87; 1.04-3.34), whilst past suicide attempts were associated with increased use of fluoxetine (2.06; 1.10-3.87) relative to sertraline.

Conclusion: There were several factors associated with different antidepressant receipt in psychiatric healthcare. In patients aged >25, those on fluoxetine were more likely to have past suicide attempt, while past use of antidepressant and non-antidepressant use was also associated with use of new generation antidepressants, potentially reflecting perceived treatment resistance.

Keywords: antidepressant use; depressive disorders; secondary care; psychiatric service; clinical factors; antidepressant prescription

Strengths and Limitations of this study

- To our knowledge, this is the first study profiling correlates of antidepressant use in a cohort of patients receiving treatment in a mental health service setting in the UK.
- The data included hard to measure variables such as depressive symptoms, derived using text mining algorithms.
- Focusing on antidepressant data in a 6-month window limited sample sizes for some analyses.
- The analysis is cross-sectional and causal relationships cannot be inferred from associations observed.
- The duration of the antidepressant treatment before and during the observation period was not known.

Introduction

There are standard national guidelines directing antidepressant prescription in secondary care¹ (secondary care refers to non-first-line treatment services provided by health professionals to patients who are usually referred by their primary care provider such as general practitioner). British guidelines for the management of depression in secondary care specify that care plans should involve, among other things, the development of a crisis plan that identifies and details management of potential triggers for a depressive episode or a worsening of existing symptoms¹. However in practice a range of patient and clinician characteristics may influence antidepressant prescription^{1,2}. For example, a community based study of data collected from 10 psychiatrists who offered antidepressant treatment to 1137 patients found that this was influenced by avoidance of side effects, the presence of comorbidities and the presence of specific depressive symptoms such as anxiety, insomnia, fatigue, irritability or increased appetite³. Supporting these results, studies profiling antidepressant prescriptions have established that patient-clinician relationships, past experiences with medication and patient symptoms can influence antidepressant prescription; however, to date these have been set in primary care⁴⁻⁷.

There are few studies investigating factors associated with antidepressant use in a secondary mental healthcare setting^{8,9}, where antidepressant use is common, albeit more frequently in cases where first-line treatment has been ineffective or is complex for other reasons¹⁰. The limited availability of secondary mental health care (compared to primary care) data for research^{11,12}, has presented wider challenges for the identification of treatment receipt and response¹³, compounded by the limited availability of data on important clinical parameters such as depressive symptoms¹⁴ due to variation in clinical recording practices¹⁵. Limited data availability can be countered by novel approaches to information extraction applied to health records databases. For example, natural language processing techniques are being introduced in psychiatric research to help with data extraction on varying levels¹⁶. In a systematic review, Abbe et al¹⁶ identified 38 studies using natural language processing techniques for psychiatry-related research, including analyses of patient perspectives on diagnosis and treatment, detecting diagnosis based on frequency of use of relevant terms, analyses of medical literature, and analyses of psychiatric clinical records. The review emphasized the potential value of text mining but also the unique challenges faced in this field, such as the mentions of emotions and subtle descriptions of personality or characteristics which may indicate symptomatology, the challenge of distinguishing of terms with multiple meanings, and the requirement for very large training corpora to achieve robust results.

To the best of our knowledge there has not been a study profiling antidepressant prescription in the UK, outside of primary care^{17,18}. The objective of our study was to investigate whether clinical symptoms

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(extracted with help of text mining techniques), past antidepressant or other psychotropic treatment or demographic factors are associated with different antidepressant treatment schedules used for depressive disorders in a secondary psychiatric healthcare setting.

For peer review only

Methods

The Dataset

The Clinical Record Interactive Search (CRIS) system provides de-identified case note information from the South London and Maudsley (SLaM) NHS Trust, a large mental healthcare provider serving a geographic catchment of approximately 1.3 million residents in four south London boroughs (Lambeth, Southwark, Lewisham, and Croydon). Electronic health records (EHRs) have been used comprehensively across all SLaM services since 2006. CRIS was established in 2008 to allow searching and retrieval of de-identified¹⁹ clinical information for research purposes within a robust, patient-led governance framework, and currently houses records on over 270,000 cases^{20,21}. The system allows for retrieval of information from de-identified structured and free-text fields, and the use of CRIS for research was approved by the Oxfordshire Research Ethics Committee C (reference 08/H0606/71+5). Patient consent was not required due to research data being pseudonymised.

Observation Window and Inclusion Criteria

A 6-month interval from 1st March to 31st August 2015 was selected as the observation period where type of antidepressant use, defined as single antidepressant use and antidepressants users on two antidepressants (referred to here as binary antidepressant use) represented the main dependent variable. All antidepressant use groups were mutually exclusive as described in the next section. Independent variables (demographic and clinical variables) were extracted over the 12 months prior to the observation window and their associations with antidepressant use within the observation window were analysed.

Patients were included if they received active SLaM care within the 6-month observation interval, and if they had received any of the following clinical diagnoses according to 10th Revision of the International Classification of Diseases (ICD-10) codes on or before the 31st of August 2015: depressive episode (F32), recurrent depressive disorder (F33), dysthymia (F34.1), and/or mixed anxiety and depression (F41.2). Individuals were excluded if they had received any F01-F09 (organic disorders), F20-F29 (schizophrenia-like disorders) or F31 (bipolar disorder) diagnoses. Active care was defined as at least one face-to-face contact with SLaM service within the observation window.

Antidepressant Use

1
2
3 Antidepressant use was ascertained using an algorithm developed in General Architecture for Text
4 Engineering (GATE) software,²² designed to extract data specifically on any medication recorded in free-text
5 fields (e.g. case notes, correspondence). Details of the development of this medication extraction algorithm have
6 previously been published^{14,21}. For each patient in the final cohort, any antidepressant use (regardless of the
7 duration of use) during the observation window was extracted as a binary variable. The antidepressants for
8 which data were collected comprised the following: i) tricyclic and tricyclic related - amitriptyline,
9 clomipramine, dosulepin, doxepin, imipramine, lofepramine, nortriptyline, trimipramine, mianserin and
10 trazodone; ii) mono-amine oxidase inhibitors (MAOIs) - isocarboxazid, phenelzine, tranlycypromaine and
11 moclobemide; iii) Selective Serotonin Re-uptake Inhibitors (SSRIs) - sertraline, fluoxetine, citalopram,
12 escitalopram, fluvoxamine and paroxetine; iv) Selective Norepinephrine Reuptake Inhibitors (SNRIs) -
13 venlafaxine, reboxetine and duloxetine; and v) Other classes - agomelatine, bupropion, and mirtazapine.

14
15
16
17
18
19
20
21
22 The final cohort comprised 1,561 patients. The most common mutually exclusive monotherapy
23 antidepressant used within the 6-month window was sertraline (360 patients), followed by mirtazapine (305),
24 citalopram (213), fluoxetine (200), venlafaxine (143), escitalopram (52). The most common mutually exclusive
25 double antidepressant combinations were any one SSRI with mirtazapine (110), any one SNRI with mirtazapine
26 (89) and a combination of any two SSRIs (89). Groups with no antidepressant use data (n = 1936) were
27 excluded, as were groups with less than 50 patients (to avoid small cell sizes) and those where algorithms
28 indicated use of three or more antidepressants (n = 494). All antidepressant groups were mutually exclusive.

37 **Covariates**

38
39 Apart from demographic variables, all other covariate data were extracted from data recorded within
40 the 12 months prior to the observation window. Demographic variables were extracted from structured fields,
41 but all other data variables (listed below) were individually extracted using GATE and TextHunter, two text
42 mining software tools which can be programmed to extract data from free-text notes via rules-based and
43 machine learning techniques, respectively. All clinical symptom data variables were extracted using
44 TextHunter.

45
46
47
48
49 **Demographic variables:** Ethnic group, age, gender, marital status were extracted from structured
50 fields in the source record. Area-level deprivation was measured from the Index of Multiple Deprivation (IMD)
51 that is derived from 2011 national Census data for each individual address, aggregated to Lower Super Output
52 Areas – geographic units with a mean of 1500 inhabitants. The widely-used IMD score combines Census-
53
54
55
56
57
58
59

1
2
3 derived data across multiple domains (income, employment, health, education, barriers to housing/ services,
4 living environment, crime) and ranks each area at a national level²³.

6 **Diagnosis-derived depression severity:** Based on the latest-recorded diagnostic code, depression
7 severity was estimated in three categories – Mild, Moderate/Severe and Unspecified. *Mild severity* included
8 diagnoses of F32.0 Mild depressive episode, mild, F34.0 recurrent depressive episode, mild, F34.1 dysthymia
9 and F41.2 mixed anxiety and depressive disorders. *Moderate-to-Severe depressive severity* included diagnoses
10 of F32.1 moderate depressive episode, F32.3 severe depressive episode with psychotic episode, F32.2 severe
11 depression without psychotic episode, F33.1 recurrent depressive episode, current episode moderate, F33.3 and
12 F33.2 (respectively) recurrent depressive episode with and without psychotic episode, and F33.8 other recurrent
13 depressive, unspecified. *Unspecified severity* was defined where there was no specified severity of depression
14 within the ICD-code of depression, such as F32 – Depressive episode (unspecified severity), other depressive
15 episodes, depressive episode, unspecified, F33- recurrent depressive disorder (unspecified severity), F33.4
16 recurrent depressive in remission (unspecified severity).
17
18
19
20
21
22
23
24
25

26 **Past medication/therapy use:** Antipsychotic, benzodiazepine, mood stabilizer and antidepressant use in
27 the preceding 12 months were ascertained, as were the duration of the current treatment episode, any inpatient in
28 the past 12 months, psychotherapy in the past 12 months, and referral to Improving Access to Psychiatric
29 Treatment (IAPT) services. IAPT services are a nationwide initiative introduced to increase access to
30 psychological treatments for common mental disorders in primary care.
31
32
33
34

35 **Clinical symptom data:** As described, bespoke natural language processing algorithms were applied to
36 ascertain symptoms mentioned as present in text fields from the source electronic records. Data on fourteen
37 symptoms of depression were extracted on text fields from the preceding 12 months. To avoid small patient
38 groups for analysis, depressive symptoms were categorised into sub-scales supported by previous results from
39 confirmatory factor analysis on depression scale items (Beck Depressive Inventory-II) in a clinical psychiatric
40 population²⁴ and subsequently supported by other findings^{25,26} albeit with possible variation in factors at older
41 ages²⁷. Hence the groupings were as follows: *Cognitive symptoms*: helplessness, worthlessness and
42 hopelessness; *Affective symptoms*: anhedonia, poor motivation, apathy and low mood; *Somatic symptoms*: poor
43 concentration, agitation, irritability, low energy, insomnia, poor appetite and anergia. In addition, the presence
44 of *psychotic symptoms* over the previous 12 months were ascertained from algorithms for hallucinations and
45 delusions. For these symptom groups, in order to minimise false positive occurrences, 2 or more mentions of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 symptoms in that domain were classified as a positive instance. *Suicidal behaviour* was ascertained over the
4 preceding 12 months using natural language processing algorithms for suicidal ideation and suicide attempt.
5
6
7

8 **Patient and Public Involvement**

9
10 Patients and public were not directly involved in this study, although all projects using the CRIS data
11 resource are considered and approved by a patient-led Oversight Committee¹⁹.
12
13

14 **Statistical Analysis**

15
16 Group differences were analysed using chi-squared tests for categorical variables, using t-tests or one-
17 way ANOVAs for normally distributed continuous variables, and using the Kruskal-Wallis test for non-
18 normally distributed continuous data. Multinomial logistic regression analyses were used to answer the research
19 question. The probability of receiving any of the common antidepressant treatments relative to sertraline (the
20 referent, most used, antidepressant category) was estimated using exponentiated regression coefficients from the
21 multinomial regression which represents Relative Risk Ratios (RRR). To build a representative model of which
22 correlates predict antidepressant use in secondary care, decisions to include variables in the final model were
23 guided by the association of each variable in an initial model including age and gender as covariates. Variables
24 that did not have any significant associations in age- and gender- adjusted analysis were not included in the final
25 model. For initial selection based on age- and gender- adjusted analysis, the significance was set at $p \leq 0.25$ ²⁸.
26 This was to help minimise i) exclusion of potentially key covariates and ii) inclusion of $p < 0.05$ significant
27 estimates occurring by chance. The selected variables were then simultaneously entered in a full model. In the
28 fully adjusted model significance level was set at $p < 0.05$ for retaining variables. The correlates retained in the
29 final multinomial regression model were age, gender, past inpatient status, past benzodiazepine use, past
30 antipsychotic use, past mood stabiliser use, past antidepressant use, past psychotherapy and IAPT referrals, past
31 experience of psychotic, somatic, affective and cognitive symptoms; and past experience of suicidal ideation
32 and past suicide attempts. In addition, separate analysis was conducted in those aged 26 and over, on the
33 assumption that different factors may be taken into consideration when considering prescriptions of
34 antidepressants to children, adolescents and young people relative to adults^{1,29}.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Any missing values were treated as null values in the analysis as they formed less than 5% of data. As
52 part of sensitivity analysis, and to ensure important variables are not being excluded in the final model, a full
53 multivariable model was analysed and any variables that were statistically and clinically non-significant were
54
55
56
57
58
59
60

1
2
3 then removed from the model. The results from the final models (from the entire cohort analysis and the adult-
4 only cohort) are available in Appendix for comparison.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Results

Table 1 compares patient characteristics between patients using and not using antidepressants. Groups differed in age, ethnicity and deprivation with patients on antidepressants being older, less deprived and of white background. Table 2 compares each antidepressant or antidepressant combination group by demographics, referral data, past medication use and past psychological therapy referral. The demographic and clinical differences between the antidepressant groups are statistically significant apart from ethnicity, area-level deprivation and having had a past referral for psychotherapy. Notably, patients receiving fluoxetine were younger, whilst older patients were over-represented in those receiving a combination of newer antidepressants such as mirtazapine and a SNRI; there were more males receiving mirtazapine than females; most of the antidepressant users were single, and only a minority had recorded non-antidepressant psychotropic treatments or psychotherapy in the past. Table 3 indicates that the majority of patients had a moderate to severe diagnosis of depression, a large majority of whom were not recorded as having experienced suicidal ideation or attempted suicide in the preceding 12 months. Apart from diagnostic severity and past psychotic symptoms, for all other past depressive symptoms and past suicidal ideation and attempts, the analysis indicated significant heterogeneity across the antidepressant user groups.

Tables 4 and 5 show the Relative Risk Ratio (RRR), estimating the probability of patients being on any antidepressant relative to sertraline (the most common antidepressant received in our cohort), derived from the fully adjusted multinomial logistic regression models in the entire cohort and the adult-only cohort respectively. Table 4 shows that relative to females, males are more likely to be on mirtazapine relative to sertraline. It also indicates that patients on newer antidepressants are more likely to have used non-antidepressant psychotropic medication or been on antidepressants in the past. Those on citalopram or fluoxetine are less likely to have experienced affective symptoms (such as low mood and poor motivation) in the past compared to those on sertraline, whilst those who have experienced somatic symptoms (such as insomnia and agitation) in the past are more likely to be on mirtazapine relative to sertraline. In the entire cohort and in those aged >25, older age was associated with higher probability of being prescribed new generation antidepressants, namely – a combination of any one SNRI and mirtazapine, a combination of any one SSRI and mirtazapine, mirtazapine, and venlafaxine compared to sertraline. In the entire cohort older age was associated with a decreased probability of being prescribed any one SSRI (Table 4 and 5) compared to sertraline.

The results from the analysis in those aged >25 (Table 5) show increased likelihood of males being on mirtazapine compared to females. They also show that, relative to sertraline, patients on citalopram or fluoxetine

1
2
3 are less like to have recorded affective symptoms, patients on mirtazapine are more likely to have recorded
4 somatic symptoms, and patients on fluoxetine were more likely to have a recorded suicide attempt in the past 12
5 months relative to those on sertraline. The sensitivity analyses did not give rise to any marked difference in
6 findings (see Appendix).
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The aim of this study was to ascertain patient demographic and clinical factors that correlate with different antidepressant treatments in patients actively receiving secondary mental health care for clinical depression. While there were no strongly consistent trends across all comparison groups or exposures, our results suggest that age, past medication and/or psychotherapy receipt use and symptom profiles in the past 12 months have potentially some influence on antidepressant receipt in secondary mental healthcare.

We found that older patients were less likely to be using fluoxetine or a combination of two SSRIs relative to sertraline and were more likely to be on other combinations, citalopram, mirtazapine or venlafaxine. Comparable to our findings, a study of newly initiated antidepressant use in a cohort of over 500,000 war veterans with a diagnosis of depression⁹ found that older patients were less likely (RRR 0.70) to have started on fluoxetine than sertraline. While we did not seek to collect data on the reasoning behind the choices, although this might reflect concerns around the longer half-life of fluoxetine in older age groups and the lower propensity of sertraline for cytochrome-related interactions with co-prescribed medications, the association was less strong in the sub-group aged >25, so might be more likely to reflect lower perceived risk of treatment-emergent suicidality associated with fluoxetine in adolescents and younger adults. Similarly, the association of older age with mirtazapine use, individually or in combination, may reflect perceived likelihood of sedation and weight gain – considered problematic in younger patients but potentially advantageous (when taken at night) in late life depression. On the other hand the higher use of mirtazapine (compared to sertraline) in men, compared to women, may reflect lower incidence of sexual dysfunction side-effects³⁰. Of interest, we found no substantial variation in use by ethnicity, marital status or neighbourhood socioeconomic status, once age and gender had been accounted for, suggesting little evidence of socially determined variation in prescribing.

Considering past medication use, antipsychotic, mood stabiliser or antidepressant use in the previous 12 months was associated with a higher likelihood of the co-occurrence of SNRI with mirtazapine during the observation period, and mood stabiliser use was also predictive of venlafaxine compared to sertraline use. The SNRI-mirtazapine group were also more likely to have been referred for primary care based psychotherapy (the UK's IAPT service model). As this secondary care cohort is likely to have an over-representation of individuals with some resistance to first line antidepressant treatment, it may follow that these individuals were on other treatment regimes in the past and that newer antidepressant regimes were being prescribed in the context of higher levels of treatment resistance. However, it is hard to define, and therefore identify, patients who are resistant to antidepressant treatment especially from naturalistic clinical databases, so conclusions can only be

1
2
3 tentative.

4
5 Considering clinical features, suicidal ideation and past suicide attempts were not significantly
6 associated with different antidepressant use overall; however, past suicide attempt was associated with an
7 increased likelihood of fluoxetine compared to sertraline receipt in patients aged >25 which, as discussed above
8 for age effects, may reflect the evidence collated from meta-analyses of randomized controlled trials and
9 observation studies where fluoxetine has been shown to carry reduced risk of emergent suicidal behaviour in
10 adults compared to children and adolescents³¹⁻³³. Those with affective symptoms recorded were less likely to be
11 on citalopram or fluoxetine than sertraline, while those with somatic symptoms were more likely to be on
12 mirtazapine, associations which persisted in the cohort aged >25. Clinician prescribing preference may be
13 influenced by perceived therapeutic actions or perceived risk of adverse drug events, or both. For example, the
14 somatic symptoms of poor appetite and insomnia may increase the likelihood of a medication such as
15 mirtazapine being prescribed because of recognised propensity to sedation and weight gain. There is some
16 evidence to suggest citalopram may induce cardio toxicity in overdose³⁴; however, apart from clinical guidelines
17 on when to prescribe antidepressants studies are rarely conducted to assess the association singular drugs with
18 depressive symptoms are being prescribed³⁵.

19
20 As mentioned, there has been very little previous research into factors associated with different
21 antidepressant treatments for depression, particularly in secondary care. Improved knowledge in this area is
22 important for several reasons. Firstly, it is helpful to understand factors potentially influencing prescribing
23 behaviour to assess the impact of guidelines and to describe variations beyond guidelines. From our
24 observations here, the relative lack of covariates consistently associated with antidepressant use suggests
25 prescribing based on individual experiences after patient-clinician communication, consistent with national
26 guidelines emphasising patient-clinician communication³⁵. However, findings suggestive of prescribing
27 motivations derived from observational data of this nature need further qualitative studies for confirmation.
28 Secondly, while variations in prescribing may reflect potentially problematic non-evidence-based behaviour, it
29 might also highlight novel patterns arising from clinical experience which need to be noted and assessed further
30 to improve the evidence base. Early detection of adverse, or unexpectedly beneficial, effects is an example of
31 this. indications of how antidepressants are being used for treatment in secondary care is more realistic than
32 research from pharmaceutical trials. Our findings suggest that there are certain antidepressants that are avoided
33 in certain clinical scenarios; for example, patients previously described as having symptoms in the 'affective'
34 category were less likely to be receiving citalopram or fluoxetine compared to sertraline. There is a suggestion
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 from the results that newer generation antidepressants are used to treat more severe depression which may
4 indicate greater clinician-perceived tolerability and/or lower toxicity and/or lower propensity to interact with
5 other co-prescribed medication^{35,29}.
6
7

8 The results should be interpreted with study limitations in mind. First, using antidepressant data in a 6-
9 month window limited sample sizes for analysis, and inaccurate measures of exposure status (for example, the
10 use of area- rather than individual-level socioeconomic status) might have reduced the likelihood of identifying
11 underlying associations. Second, the study is close to cross-sectional design, since there may have been co-
12 occurrence of exposures and outcomes in the prior 12-month observation period; therefore direct causal
13 relationships cannot be conclusively inferred. Third, the duration of the antidepressant treatment during the
14 observation period was not known, so some patients will have been new users of antidepressants identified,
15 while others may have been using the antidepressant(s) for much longer periods of time; similarly, where there
16 was co-occurrence of two antidepressants during the time period evaluated, it was not possible to distinguish a
17 switch from one agent to another from co-prescribing of the two agents. Fourth, the results of the study cannot
18 assumed to be generalizable to all patients in secondary mental healthcare settings due to the social and ethnic
19 diversity found in south east London from where this sample was drawn; in addition, the focus of the study was
20 on antidepressant use in people with a depressive disorder diagnosis and being reviewed in secondary mental
21 healthcare, so findings cannot assumed to generalise to antidepressant use in other circumstances or for other
22 indications. Finally, we could only investigate factors that were available to us in the current dataset. The
23 literature reports various clinical covariates⁸, patient demographics⁹, medication use³⁶, clinician characteristics³
24 and clinical location^{8,9} as factors involved for antidepressant prescription in secondary mental healthcare
25 settings. We could not capture all these factors in our analysis.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Limitations notwithstanding there are key strengths to this paper. To our knowledge this is the first
41 study profiling antidepressant use in a cohort of patients receiving treatment for depression in a secondary
42 mental health care setting in the UK. Although from a single site, the use of health records data provides a more
43 generalisable sample than would be possible through a conventional cohort design involving *de novo* interviews,
44 let alone through the even more selected samples in clinical trials. In addition, the data included constructs such
45 as depressive symptoms that are not usually available in administrative 'big' data, taking advantage of a suite of
46 recently developed text mining algorithms to capture a greater depth of data from free-text fields, circumventing
47 the usual restriction of analysed data to those recorded in structured fields. The findings have the potential to
48 inform clinical practice within this clinical setting. Knowledge of factors involved in antidepressant prescription
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 could be used to audit clinical practices and inform whether the clinical practices are benefitting patient
4 treatment outcomes³⁷. However, further qualitative work is definitely indicated to identify and highlight
5 processes involved in clinician-selection of antidepressant treatment. Continual monitoring of treatment choices
6 in this cohort may contribute to providing optimal care for secondary care patients and there may be scope for
7 further quantitative evaluation not only across a wider range of services, but also evaluating longer-term
8 outcomes associated with different treatment decisions.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Acknowledgements:* The authors of this work thank MD for initial advice and guidance on the statistical
4 analysis, and extend sincere gratitude to MK for his patient and continuous support on statistical analysis.
5

6 *Contributors:* RS, RD and AF conceived of the study and were responsible for the design and search strategy.
7
8 AF, HS and DC were responsible for data extraction. AF was responsible for conducting the analysis and
9 producing the tables. The analysis was guided by MD initially and then MK. The initial draft of the manuscript
10 was prepared by AF then circulated among all authors for revision. All authors helped to evolve analysis plans,
11 interpret data and critically revise successive drafts of the manuscript.
12
13
14

15 *Funding statement:* The National Institute for Health Research (NIHR) Biomedical Research Centre at South
16 London and Maudsley NHS Foundation Trust, King's College London and Mental Health Research UK.
17

18 *Funding:* DC, HS, RD and RS are part-funded by the National Institute for Health Research (NIHR) Biomedical
19 Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. AF is
20 funded by a Mark Robinson studentship awarded by Mental Health Research UK.
21
22
23

24 *Competing interests:* None.
25

26 *Provenance and peer review:* Not commissioned; externally peer reviewed.
27

28 *Data sharing statement:* No additional data available.
29

30 *Statement on manuscript:* The lead author (the manuscript's guarantor) affirms that the manuscript is an honest,
31 accurate, and transparent account of the study being reported; that no important aspects of the study have been
32 omitted; and that any discrepancies from the study as planned have been explained.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 National Institute for Health & Clinical Excellence (NICE) Guideline. National Clinical Practice
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 National Institute for Health & Clinical Excellence (NICE) Guideline. National Clinical Practice
Guideline 90: Depression The NICE Guidelines on the Treatment and Management of Depression in
Adults - The Updated Edition. The British Psychological Society and The Royal College of
Psychiatrists, 2010.
- 2 Zetin M, Hoepner CT, Bjornson L. Rational Antidepressant Selection: Applying Evidence-Based
Medicine to Complex Real-World Patients. *Evid Based Med* 2006; **39**: 38–104.
- 3 Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, *et al*. Which Factors
Influence Psychiatrists' Selection of Antidepressants? *Am J Psychiatry* 2004; **161**: 1285–9.
- 4 Meijer WEE, Heerdink ER, Leufken HGM, Herings MC, Egberts ACG, Nolen WA. Incidence and
determinants of long-term use of antidepressants. *Eur J Clin Pharmacol* 2004; **60**: 57–61.
- 5 Sleath B, Shih YCT. Sociological influences on antidepressant prescribing. *Soc Sci Med* 2003; **56**:
1335–44.
- 6 Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, *et al*. Prescribing patterns of
antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research
(FINDER) study. *Eur Psychiatry* 2008; **23**: 66–73.
- 7 Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. *Ann Pharmacother*
2000; **34**: 10–4.
- 8 Kim HM, Zivin K, Choe HM, Stano CM, Ganoczy D, Walters H, *et al*. Predictors of Start of Different
Antidepressants in Patient Charts among Patients with Depression. *J Manag Care Spec Pharm* 2015;
21: 424–30.
- 9 Kim HM, Zivin K, Ganoczy D, Pfeiffer P, Hoggatt K, McCarthy JF, *et al*. Predictors of alternative
antidepressant agent initiation among U.S. veterans diagnosed with depression. *Pharmacoepidemiol*
Drug Saf 2010; **19**: 1049–56.
- 10 Huxley P, Goldberg D. Mental health in the community: the pathways to psychiatric care. *London*
Tavistock Publ 1980.
- 11 Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of
electronic health records for secondary use. *J Biomed Inform* 2013; **46**: 830–6.
- 12 Thiru K, Hassey A, Sullivan F. Primary care patient record data in primary care. 2001; : 1–5.
- 13 Kashner J. How Good Are Observational Studies in Assessing Psychiatric Treatment Outcomes? 2009; :

- 1
2
3 244–7.
- 4 14 Jackson RG, Ball M, Patel R, Hayes RD, Dobson RJB, Stewart R. TextHunter – A User Friendly Tool
5 for Extracting Generic Concepts from Free Text in Clinical Research. *Proc Am Med Informatics Assoc*
6 2014; : 729–38.
7
8
9
- 10 15 Mathioudakis A, Rousalova I, Gagnat AA, Titus C. How to keep good clinical records. 2016; **12**: 371–5.
- 11 16 Abbe A, Grouin C, Zweigenbaum P, Falissard B. Text mining applications in psychiatry: a systematic
12 literature review. *Int J Methods Psychiatr Res* 2016; **25**: 86–100.
13
14
- 15 17 Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, *et al*. Influences on antidepressant
16 prescribing trends in the UK: 1995–2011. *Soc Psychiatry Psychiatr Epidemiol* 2017; **52**: 193–200.
17
18
- 19 18 Shi N, Durden E, Torres A, Cao Z, Happich M. Predictors of Treatment with Duloxetine or Venlafaxine
20 XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom.
21 *Depress Res Treat* 2012; **2012**.
22
23
- 24 19 Fernandes AC, Cloete D, Broadbent MTM, Hayes RD, Chang C, Jackson RG, *et al*. Development and
25 evaluation of a de-identification procedure for a case register sourced from mental health electronic
26 records. *BMC Med Inform Decis Mak* 2013; **13**: 1–14.
27
28
- 29 20 Stewart R, Soremekun M, Perera G, Broadbent M, Callard F, Denis M, *et al*. The South London and
30 Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register:
31 development and descriptive data. *BMC Psychiatry* 2009; **9**: 51.
32
33
- 34 21 Perera G, Broadbent M, Callard F, Chang C, Downs J, Dutta R, *et al*. Cohort profile of the South
35 London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case
36 Register : current status and recent enhancement of an Electronic Mental Health Record-derived data
37 resource. *BMJ Open* 2016; : 1–22.
38
39
- 40 22 Cunningham H, Maynard D, Bontcheva K, Tablan V, Aswani N, Roberts I, *et al*. *Text Processing with*
41 *GATE (Version 6)*. University of Sheffield Department of Computer Science, 2011.
42
43
- 44 23 DCLG D for C and LG. The English Index of Multiple Deprivation. 2015. .
45
46
- 47 24 Arnarson P, Olason D, Smari J, Sigurdsson JF. The Beck Depression Inventory Second Edition student
48 and patient populations The Beck Depression Inventory Second Edition (BDI-II): Psychometric
49 properties in Icelandic student and patient populations. *Nord J Psychiatry* 2009; **62**: 360–5.
50
51
- 52 25 Ward LC. Comparison of Factor Structure Models for the Beck Depression Inventory — II. *Psychol*
53 *Assess* 2006; **18**: 81–8.
54
55
56
57
58
59
60

- 1
2
3 26 Subica AM, Fowler JC, Elhai JD, Frueh BC, Sharp C, Kelly EL, *et al.* Factor Structure and Diagnostic
4 Validity of the Beck Depression Inventory-II With Adult Clinical Inpatients: Comparison to a Gold-
5 Standard Diagnostic Interview. *Psychol Assess* 2014; **26**: No-Specified.
6
7
8 27 Prince MJ, Reischies F, Beekman AT, Fuhrer R, Jonker C, Kivela SL, *et al.* Development of the EURO-
9 D scale--a European, Union initiative to compare symptoms of depression in 14 European centres. *Br J*
10 *Psychiatry* 1999; **174**: 330–8.
11
12
13 28 Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic
14 regression. *Source Code Biol Med* 2008; **3**: 17.
15
16
17 29 Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, *et al.* Evidence-based guidelines
18 for treating depressive disorders with antidepressants: A revision of the 2000 British Association for
19 Psychopharmacology guidelines. *J Psychopharmacol* 2015; **29**: 459–524.
20
21
22 30 Saiz-Ruiz J, Montes J, Ibanez A, Diaz M, Vicente F, Pelegrin C, *et al.* Assessment of Sexual
23 Functioning in Depressed Patients Treated With Mirtazapine: A Naturalistic 6-Month Study. *Hum*
24 *Psychopharmacol Clin Exp* 2005; **6**: 435–40.
25
26
27 31 Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a
28 systematic review of observational studies. *CMAJ* 2009; **3**: 291–7.
29
30
31 32 Gibbons RD, Brown CH, Hur K, Davis J, Mann J. Suicidal thoughts and behavior with antidepressant
32 treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Arch*
33 *Gen Psychiatry* 2012; **69**: 580–7.
34
35
36 33 Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin
37 reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.
38 *Lancet* 2004; **363**: 1341–5.
39
40
41 34 Cleare A, Pariante C, Young A, Anderson I, Christmas, D. Cowen P. *Antidepressants*., May. *Evidence-*
42 *based guidelines for treating depressive disorders with Psychopharmacology, a revision of the 2008*
43 *British Association for guidelines.* , 2015 doi:10.1177/0269881107088441.
44
45
46 35 NHS. Formulary and Prescribing Guidelines: Providing Partnership Services in Bedfordshire, Essex and
47 Luton. 2011; : 1–12.
48
49
50 36 Sirey JA, Meyers BS, Bruce ML, Alexopoulos GS, Perlick DA, Raue P. Predictors of Antidepressant
51 Prescription and Early Use Among Depressed Outpatients. *Am J Psychiatry* 1999; **156**: 690–6.
52
53
54 37 Lin SY, Stevens MB. The Symptom Cluster-Based Approach to Individualize Patient-Centered
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Treatment for Major Depression. *J Am Board Fam Med* 2014; **27**: 151–9.

For peer review only

Table 1: Comparing characteristics between patients receiving or not receiving antidepressants during the 6-month evaluation period (N = 3497).

| Patient Characteristics | On single or dual therapy antidepressants N=1561 | Not on antidepressants N=1936 | |
|---|---|----------------------------------|-------------------------------------|
| Gender | | | |
| Female | 1229 | 1295 | $\chi^2 = 0.07$, df = 1, p = 0.80 |
| Male | 706 | 759 | |
| Mean age | 44.3 years | 40.1 years | t = -7.6, df = 3908, p < 0.001 |
| Marital status | | | |
| Single | 1091 (56.3%) | 1302 (63.4%) | $\chi^2 = 0.02$, df = 2, p = 0.999 |
| Married | 456 (23.5%) | 319 (15.5%) | |
| Other | 389 (20.0%) | 434 (21.1%) | |
| Area-level deprivation score tertile | | | |
| 2.25 – 22.3 (least deprived) | 631 (33.0%) | 580 (28.7%) | $\chi^2 = 9.1$, df = 2, p < 0.05 |
| 22.4 – 42.3 | 1099 (57.6%) | 1224 (60.6%) | |
| 42.4 – 62.3 (most deprived) | 179 (9.4%) | 215 (10.6%) | |
| Ethnicity | | | |
| White | 1220 (63.9%) | 864 (42.1%) | $\chi^2 = 10.5$, df = 1, p < 0.01 |
| Other | 716 (36.1%) | 1191 (57.9%) | |
| Depression severity from diagnosis | | | |
| Mild | 383 (24.5%) | 460 (28.3%) | $\chi^2 = 0.007$, df = 2, p = 0.99 |
| Moderate-Severe | 845 (54.1%) | 845 (48.4%) | |
| Unspecified | 333 (21.3%) | 379 (23.3%) | |

Table 2: Comparison of demographic characteristics, past service use, and past psychotropic medication use by antidepressant category

| | Any one SNRI and Mirtazapine N=89 | Any one SSRI and Mirtazapine N=110 | Any two SSRIs N=89 | Citalopram N=213 | Escitalopram N=52 | Fluoxetine N=200 | Mirtazapine N=305 | Sertraline N=360 | Venlafaxine N=143 | Total N=1561 (%) | Test statistic; p-value c, d |
|--|--|---|--------------------------|---------------------|----------------------|---------------------|----------------------|---------------------|----------------------|---------------------|---------------------------------------|
| DEMOGRAPHICS | | | | | | | | | | | |
| Mean Age in years [SD] | 52.9 [16.6] | 48.6 [18.6] | 34.1 [16.2] | 42.7 [15.5] | 44.1 [16.3] | 33.3 [16.0] | 49.2 [18.8] | 39.3 [16.8] | 48.8 [18.1] | 43.8 [18.2] | 25.38; |
| Median Age in years | 52 | 48 | 33 | 42 | 44 | 30 | 47 | 38 | 48 | 41 | <0.001 |
| Gender: Female | 60 (67.4%) | 65 (59.6) | 64 (71.9) | 147 (69) | 35 (67.3) | 139 (69.5) | 138 (45.2) | 251 (69.7) | 91 (63.6) | 990 (63.4) | 60.07; |
| Male | 29 (32.6%) | 44 (40.4) | 25 (28.1) | 66 (31) | 17 (32.70) | 61 (30.5) | 167 (54.8) | 109 (30.3) | 52 (36.4) | 571 (36.6) | <0.001 |
| Ethnicity: White | 61 (68.5%) | 69 (62.7) | 49 (55.1) | 135 (63.4) | 39 (75) | 127 (63.5) | 176 (57.7) | 213 (59.2) | 101 (70.6) | 970 (62.1) | 15.70; |
| Other | 28 (31.5%) | 41 (37.3) | 40 (44.9) | 78 (36.6) | 13 (25) | 73 (36.5) | 129 (42.3) | 147 (40.8) | 42 (29.4) | 591 (37.9) | 0.05 |
| Marital Status: Single | 34 (38.2%) | 61 (55.5) | 47 (52.8) | 127 (59.6) | 25 (48.1) | 133 (66.5) | 169 (55.4) | 216 (60) | 79 (55.2) | 891 (57.1) | df = 16; |
| Married | 31 (34.8%) | 26 (23.6) | 24 (27.0) | 40 (18.8) | 18 (34.6) | 23 (11.5) | 72 (23.6) | 80 (22.2) | 35 (24.5) | 349 (22.3) | 37.40; |
| Other | 24 (27%) | 23 (20.9) | 18 (20.2) | 46 (21.6) | 9 (17.3) | 44 (22) | 64 (21) | 64 (17.8) | 29 (20.3) | 321 (20.6) | 0.002 |
| Area-Level Deprivation Score | | | | | | | | | | | |
| 1 st Tertile (2.25 – 22.3) | 29 (32.6%) | 27 (25.5) | 31 (34.8) | 62 (29.5) | 20 (38.5) | 64 (32.3) | 82 (27.2) | 122 (34.5) | 60 (42.9) | 497 (31.8) | df = 16; |
| 2 nd Tertile | 50 (56.2%) | 67 (63.2) | 44 (49.4) | 131 (62.4) | 26 (50) | 120 (60.6) | 184 (60.9) | 205 (57.9) | 71 (50.7) | 898 (57.5) | 26.33; |
| 3 rd Tertile (42.3 – 62.3) | 10 (11.2%) | 12 (11.3) | 14 (15.7) | 17 (8.1) | 6 (11.5) | 14 (7.1) | 36 (11.9) | 27 (7.6) | 9 (6.4) | 145 (9.3) | 0.05 |
| REFERRAL DATA | | | | | | | | | | | |
| Length of Spell: Mean years | 0.91 | 0.94 | 0.51 | 0.80 | 1.04 | 0.81 | 0.90 | 0.73 | 1.40 | 1561 | 2.00; |
| (SD) | [2.45] | [1.94] | [0.77] | [2.80] | [1.50] | [1.16] | [1.64] | [1.27] | [3.00] | | 0.043 |
| Past ^b Inpatient at SLaM: Yes | 16 (18%) | 24 (21.8) | 16 (18) | 18 (8.5) | 3 (5.8) | 13 (6.5) | 32 (10.5) | 47 (13.1) | 16 (11.2) | 185 (11.9) | 27.64 |
| No | 73 (82%) | 86 (78.2) | 73 (82) | 195 (91.5) | 49 (94.2) | 187 (93.5) | 273 (89.5) | 313 (86.9) | 127 (88.8) | 1376 (88.2) | <0.001 |
| PAST^b MEDICATION USE | | | | | | | | | | | |
| Benzodiazepine Use: Yes | 26 (29.2%) | 25 (22.7) | 19 (21.4) | 35 (16.4) | 11 (21.2) | 21 (10.5) | 71 (23.3) | 55 (15.3) | 36 (25.2) | 299 (19.1) | 28.01 |
| No | 63 (70.8%) | 85 (77.3) | 70 (78.6) | 178 (83.6) | 41 (78.8) | 179 (89.5) | 234 (76.7) | 305 (84.7) | 107 (74.8) | 1262 (80.8) | <0.001 |
| Antipsychotic Use: Yes | 39 (43.8%) | 35 (31.8) | 22 (24.7) | 46 (21.6) | 18 (34.6) | 41 (20.5) | 97 (31.8) | 92 (25.6) | 53 (37.1) | 443 (28.3) | 32.07; |
| No | 50 (56.2%) | 75 (68.2) | 67 (75.3) | 167 (78.4) | 34 (65.4) | 159 (79.5) | 208 (68.2) | 268 (74.4) | 90 (62.9) | 1118 (71.6) | <0.001 |
| Mood Stabiliser Use: Yes | 13 (14.6%) | 7 (6.4) | 5 (5.6) | 8 (3.8) | 6 (11.5) | 10 (5) | 19 (6.2) | 15 (4.2) | 21 (14.7) | 104 (6.7) | 33.48 |
| No | 76 (85.4%) | 103 (93.6) | 84 (94.4) | 205 (96.2) | 46 (88.4) | 190 (95) | 286 (93.8) | 345 (95.8) | 122 (85.3) | 1457 (93.3) | <0.001 |
| Antidepressant Use: Yes | 82 (92.1%) | 86 (78.2) | 61 (68.5) | 132 (62) | 41 (78.8) | 150 (75) | 233 (76.4) | 273 (75.8) | 114 (79.7) | 1172 (75.1) | 38.43; |
| No | 7 (7.9%) | 24 (21.8) | 28 (31.5) | 81 (38) | 11 (21.2) | 50 (25) | 72 (23.6) | 87 (24.2) | 29 (20.3) | 389 (24.9) | <0.001 |
| PAST^b PSYCHOLOGICAL THERAPY REFERRAL | | | | | | | | | | | |
| Psychotherapy Referral: Yes | 13 (14.6%) | 18 (16.4) | 11 (12.4) | 14 (6.6) | 7 (13.5) | 22 (11) | 29 (9.5) | 46 (12.8) | 19 (13.3) | 179 (11.5) | 11.03 |
| No | 76 (85.4%) | 92 (83.6) | 78 (87.6) | 199 (93.4) | 45 (86.5) | 178 (89) | 276 (90.5) | 314 (87.2) | 124 (86.7) | 1382 (88.5) | 0.200 |
| IAPT Referral: Yes | 51 (57.3%) | 50 (45.5) | 40 (44.9) | 108 (50.7) | 27 (51.9) | 77 (38.5) | 131 (42.9) | 181 (50.3) | 58 (40.6) | 723 (46.3) | 17.21 |
| No | 38 (42.7%) | 60 (54.5) | 49 (55.1) | 105 (49.3) | 25 (48.1) | 123 (61.5) | 174 (57.1) | 179 (49.7) | 85 (59.4) | 838 (53.7) | 0.028 |

a – Area-level Deprivation Tertiles (1st Tertile: Least Deprived; 3rd Tertile: Most Deprived). b – “Past” refers to the 12 months prior to the observation window. c –ANOVA, Chi-square test, t-tests or the Kruskal-Wallis tests were conducted to test differences between patient groups; d - degree of freedom (df) = 8, unless otherwise specified.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 3: Comparison of depression diagnostic severity, symptomatology and suicidality by antidepressant category

| | Any one SNRI and Mirtazapine N=89 (%) | Any one SSRI and Mirtazapine N=110 (%) | Any two SSRIs N=89 (%) | Citalopram N=213 (%) | Escitalopram N=52 (%) | Fluoxetine N=200 (%) | Mirtazapine N=305 (%) | Sertraline N=360 (%) | Venlafaxine N=143 (%) | Total N=1561 (%) | Test statistic; p-value ^{b,c} |
|----------------------------------|--|---|------------------------------|-------------------------|--------------------------|-------------------------|--------------------------|-------------------------|--------------------------|---------------------|---|
| DEPRESSION SEVERITY | | | | | | | | | | | |
| Depression Severity: | | | | | | | | | | | |
| Mild | 16 (18) | 22 (20) | 19 (21.4) | 33 (15.5) | 14 (26.9) | 41 (20.5) | 57 (18.7) | 79 (21.9) | 22 (15.4) | 303 (19.4) | df = 16; |
| Moderate to Severe | 49 (55) | 50 (45.5) | 37 (41.6) | 91 (42.7) | 18 (34.6) | 84 (42) | 185 (60.7) | 165 (45.8) | 60 (42) | 739 (47.3) | 17.44 |
| Unspecified Severity | 13 (14.6) | 13 (11.8) | 15 (16.9) | 45 (21.1) | 9 (17.3) | 29 (14.5) | 52 (17.1) | 59 (16.4) | 34 (23.8) | 269 (17.2) | 0.358 |
| PAST SYMPTOMS^a | | | | | | | | | | | |
| Psychotic Symptoms: | | | | | | | | | | | |
| Zero to One mention | 68 (76.4) | 77 (70) | 70 (78.7) | 176 (82.6) | 46 (88.5) | 168 (84) | 238 (78.1) | 293 (81.4) | 112 (78.3) | 1248 (80) | 14.33; |
| >= 2 mentions | 21 (23.6) | 33 (30) | 19 (21.3) | 37 (17.4) | 6 (11.5) | 32 (16) | 67 (21.9) | 67 (18.6) | 31 (21.7) | 313 (20) | 0.073 |
| Cognitive Symptoms: | | | | | | | | | | | |
| Zero to One mention | 62 (69.7) | 78 (70.9) | 68 (76.4) | 186 (87.3) | 45 (86.5) | 179 (89.5) | 254 (83.3) | 293 (81.4) | 111 (77.6) | 1276 (81.7) | 34.50; |
| >= 2 mentions | 27 (30.3) | 32 (29.1) | 21 (23.6) | 27 (12.6) | 7 (13.5) | 21 (10.5) | 51 (16.7) | 67 (18.6) | 32 (22.4) | 285 (18.3) | <0.001 |
| Affective Symptoms: | | | | | | | | | | | |
| Zero to One mention | 29 (32.6) | 40 (36.4) | 33 (37.1) | 119 (55.9) | 24 (46.2) | 110 (55) | 113 (37.1) | 131 (36.4) | 52 (36.4) | 651 (41.7) | 46.24 |
| >= 2 mentions | 60 (67.4) | 70 (63.6) | 56 (62.9) | 94 (44.1) | 28 (53.8) | 90 (45) | 192 (62.9) | 229 (63.6) | 91 (63.6) | 910 (58.3) | <0.001 |
| Somatic Symptoms: | | | | | | | | | | | |
| Zero to One mention | 39 (43.8) | 57 (51.2) | 49 (55.1) | 154 (72.3) | 34 (65.4) | 134 (67) | 155 (50.8) | 203 (56.4) | 85 (59.4) | 900 (57.7) | 42.07; |
| >= 2 mentions | 50 (56.2) | 53 (48.1) | 40 (44.9) | 59 (27.7) | 18 (34.6) | 66 (33) | 150 (49.2) | 157 (43.6) | 58 (40.6) | 651 (41.7) | <0.001 |
| PAST SUICIDALITY | | | | | | | | | | | |
| Suicide Ideation: Yes | 33 (37.1) | 38 (34.5) | 30 (33.7) | 40 (18.8) | 10 (19.2) | 44 (22) | 78 (25.6) | 101 (28.1) | 35 (24.5) | 409 (26.2) | 22.12; |
| No | 56 (62.9) | 72 (65.5) | 59 (66.3) | 173 (81.2) | 42 (80.8) | 156 (78) | 227 (74.4) | 259 (71.9) | 108 (75.5) | 1152 (73.8) | <0.05 |
| Suicide Attempt: Yes | 20 (22.4) | 34 (30.9) | 30 (33.7) | 39 (18.3) | 6 (11.5) | 48 (24) | 65 (21.3) | 77 (21.4) | 32 (22.4) | 351 (22.5) | 17.37; |
| No | 69 (77.5) | 76 (69.1) | 59 (66.3) | 174 (81.7) | 46 (88.5) | 152 (76) | 240 (76.7) | 283 (78.6) | 111 (77.6) | 1210 (77.5) | <0.05 |

^a – “Past” refers to the 12 months prior to the observation window; Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period

^b –ANOVA, Chi-square test, t-tests or the Kruskal-Wallis tests were conducted to test differences between patient groups;

^c - degree of freedom (df) = 8, unless otherwise specified.

Table 4: Fully adjusted relative risk ratio estimates from multinomial logistic regression models for associations of exposures with antidepressant categories (against sertraline as the referent group) in the total cohort (N = 1561)

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|--|---------------------------------------|--|--|--------------------|---------------------------------------|--|--|
| Age (year increment) | 1.05 (1.03 – 1.04)[‡] | 1.03 (1.02 – 1.04)[‡] | 0.98 (0.96 – 0.99)^{**} | 1.01 (1.00 – 1.02)^{**} | 1.01 (0.99 – 1.03) | 0.98(0.96 – 0.98)[‡] | 1.03 (1.02 – 1.04)[‡] | 1.03 (1.02 – 1.03)[‡] |
| Male gender (a) | 0.97 (0.57 – 1.76) | 1.33 (0.84 – 2.09) | 0.95 (0.56 – 1.61) | 0.95 (0.65 – 1.39) | 1.07 (0.56 – 2.01) | 1.08 (0.73 – 1.60) | 2.57 (1.85 – 3.57)[‡] | 1.16 (0.76 – 1.76) |
| Past Inpatient: Yes (b) | 1.09 (0.47 – 1.54) | 1.26 (0.59 – 2.70) | 0.97 (0.42 – 2.27) | 0.80 (0.43 – 1.88) | 0.60 (0.14 – 2.60) | 0.48 (0.21 – 1.07) | 0.68 (0.37 – 1.27) | 0.70 (0.32 – 1.54) |
| Past Benzodiazepine Use: Yes (b) | 1.30 (0.70 – 2.81) | 1.03 (0.55 – 1.90) | 1.63 (0.82 – 3.25) | 1.60 (0.94 – 2.73) | 1.77 (0.78 – 4.01) | 0.97 (0.53 -1.77) | 1.58 (1.00 – 2.50) | 1.63 (0.94 – 2.81) |
| Past Antipsychotic Use: Yes (b) | 1.78 (1.03 – 2.36)^{**} | 1.17 (0.69 – 1.99) | 0.91 (0.49 – 1.70) | 0.99 (0.63 – 1.60) | 1.53 (0.77 – 3.07) | 0.74 (0.46 – 1.17) | 1.19 (0.80 – 1.75) | 1.47 (0.91 – 2.36) |
| Past Mood Stabiliser Use: Yes (b) | 2.38 (1.04 – 6.34)^{**} | 1.23 (0.47 – 3.20) | 1.50 (0.50 – 4.36) | 0.99 (0.40 – 2.42) | 2.60 (0.93 – 7.27) | 1.65 (0.71 - 3.86) | 1.23 (0.60 – 2.55) | 2.96 (1.44 – 6.08)^{**} |
| Past Antidepressant Use: Yes (b) | 3.06 (1.34 – 7.85)^{**} | 0.95 (0.50 – 1.78) | 0.59 (0.31 – 1.10) | 0.76 (0.48 – 1.20) | 1.27 (0.55 – 2.94) | 1.42 (0.88 – 2.30) | 0.98 (0.63 – 1.53) | 1.10 (0.62 – 1.96) |
| Has had Psychotherapy treatment before: Yes (b) | 0.67 (0.31 – 1.51) | 0.91 (0.45 – 1.75) | 0.88 (0.42 – 1.86) | 0.51 (0.27 – 0.98)^{**} | 1.17 (0.48 – 2.89) | 0.91 (0.51 – 1.64) | 0.55 (0.32 – 0.94)^{**} | 0.81 (0.43 – 1.52) |
| Has been referred to IAPT services: Yes (b) | 1.90 (1.15 – 1.91)^{**} | 1.02 (0.65 – 1.60) | 0.81 (0.50 – 1.33) | 0.96 (0.68 – 1.37) | 1.18 (0.64 – 2.17) | 0.62 (0.43 - 0.91)[‡] | 0.88 (0.63 – 1.22) | 0.79 (0.53 – 1.20) |
| Psychotic Symptom: ≥2 mentions (c) | 0.82 (0.38 – 1.89) | 1.54 (0.72 – 2.71) | 1.00 (0.58 – 2.12) | 1.53 (0.95 – 3.00) | 0.67 (0.26 – 2.26) | 1.42 (0.79 – 2.51) | 1.16 (0.64 – 1.73) | 1.17 (0.54 – 1.90) |
| Cognitive Symptom: ≥2 mentions (c) | 1.37 (0.67 – 2.67) | 1.40 (0.72 – 2.76) | 1.18 (0.56 – 2.47) | 0.94 (0.54 – 1.87) | 0.96 (0.30 – 2.17) | 0.77 (0.39 – 1.44) | 0.72 (0.49 – 1.38) | 1.32 (0.76 – 2.67) |
| Affective Symptom: ≥2 mentions (c) | 0.53 (0.28 – 1.31) | 0.60 (0.24 – 1.13) | 0.93 (0.33 – 1.66) | 0.58 (0.27 – 0.83)^{**} | 0.72 (0.31 – 1.87) | 0.42 (0.22 – 0.72)[‡] | 0.79 (0.41 – 1.18) | 0.92 (0.36 – 1.32) |
| Somatic Symptom: ≥2 mentions (c) | 1.40 (0.63 – 1.78) | 1.02 (0.65 – 2.84) | 0.92 (0.47 – 2.33) | 0.65 (0.36 – 1.16) | 0.84 (0.39 – 2.40) | 1.10 (0.62 – 1.97) | 1.60 (1.00 – 2.75)^{**} | 0.70 (0.50 – 1.80) |
| Past Suicide Ideation: Yes (b) | 1.34 (0.76 – 1.33) | 1.07 (0.62 – 1.86) | 1.04 (0.57 – 1.90) | 0.80 (0.50 – 1.29) | 0.75 (0.34 – 1.68) | 0.88 (0.55 – 1.42) | 0.90 (0.60 – 1.36) | 0.79 (0.47 – 1.33) |
| Past Suicide Attempt: Yes (b) | 1.01 (0.51 – 2.05) | 1.49 (0.82 – 2.68) | 1.74 (0.95 – 3.19) | 1.23 (0.74 – 2.05) | 0.66 (0.25 – 1.74) | 1.57 (0.97 – 2.54) | 1.13 (0.72 – 1.77) | 1.18 (0.67 – 2.06) |

p-value: ‡ <0.05; †† < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

Table 5: Fully adjusted relative risk ratio estimates from multinomial logistic regression models for associations of exposures with antidepressant categories (against sertraline as the referent group) in patients aged >25 years (N = 1248)

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|--|---------------------------------------|--|--|--------------------|--|--|--|
| Age (year increment) | 1.04 (1.02 – 1.05)[‡] | 1.03 (1.01 – 1.04)[‡] | 0.99 (0.97 – 1.01) | 1.00 (0.99 – 1.02) | 1.00 (0.98 – 1.03) | 0.99 (0.98 – 1.01) | 1.03 (1.02 – 1.04)[‡] | 1.02 (1.01 – 1.04)[‡] |
| Male gender (a) | 0.87 (0.51 – 1.50) | 1.29 (0.79 – 2.11) | 0.89 (0.47 – 1.69) | 0.89 (0.59 – 1.35) | 1.04 (0.52 – 2.07) | 1.25 (0.78 – 2.00) | 2.36 (1.64 – 3.37)[‡] | 1.10 (0.70 – 1.73) |
| Past Inpatient: Yes (b) | 1.10 (0.45 – 2.69) | 0.96 (0.40 – 2.24) | 0.30 (0.07 – 1.26) | 0.83 (0.36 – 1.95) | 0.50 (0.09 – 3.23) | 0.50 (0.18 – 1.37) | 0.62 (0.31 – 1.24) | 0.61 (0.25 – 1.47) |
| Past Benzodiazepine Use: Yes (b) | 1.46 (0.76 – 2.78) | 1.25 (0.65 – 2.41) | 2.97 (1.32 – 6.68)^{**} | 1.61 (0.89 – 2.90) | 1.90 (0.80 – 4.49) | 1.13 (0.57 – 2.24) | 1.94 (1.20 – 3.16)^{**} | 1.87 (1.04 – 3.34)^{**} |
| Past Antipsychotic Use: Yes (b) | 2.02 (1.14 – 3.58)^{**} | 1.30 (0.73 – 2.32) | 1.02 (0.46 – 2.26) | 1.08 (0.66 – 1.80) | 1.55 (0.73 – 3.30) | 1.02 (0.57 – 1.80) | 1.16 (0.76 – 1.78) | 1.53 (0.92 – 2.57) |
| Past Mood Stabiliser Use: Yes (b) | 2.26 (0.97 – 5.30) | 1.03 (0.37 – 2.90) | 1.17 (0.31 – 4.44) | 0.78 (0.30 – 2.14) | 2.67 (0.91 – 7.76) | 1.75 (0.68 – 4.47) | 1.27 (0.60 – 2.71) | 2.76 (1.28 – 5.97)^{**} |
| Past Antidepressant Use: Yes (b) | 2.70 (1.07 – 6.86)^{**} | 0.81 (0.41 – 1.61) | 0.44 (0.20 – 0.95)^{**} | 0.72 (0.43 – 1.21) | 2.07 (0.43 – 5.54) | 1.07 (0.20 – 1.96) | 0.83 (0.50 – 1.36) | 1.09 (0.60 – 2.05) |
| Has had Psychotherapy treatment before: Yes (b) | 0.80 (0.36 – 1.76) | 1.30 (0.64 – 2.63) | 0.95 (0.33 – 2.71) | 0.52 (0.24 – 1.15) | 1.75 (0.66 – 4.57) | 1.12 (0.51 – 2.44) | 0.68 (0.38 – 1.23) | 0.86 (0.43 – 1.73) |
| Has been referred to IAPT services: Yes (b) | 2.04 (1.20 – 3.48)^{**} | 0.99 (0.60 – 1.62) | 0.93 (0.50 – 1.73) | 1.00 (0.67 – 1.50) | 1.36 (0.70 – 2.66) | 0.98 (0.61 – 1.68) | 0.93 (0.64 – 1.34) | 0.83 (0.53 – 1.31) |
| Psychotic Symptom: >2= mentions (c) | 0.81 (0.39 – 1.69) | 1.67 (0.85 – 3.26) | 0.88 (0.36 – 2.22) | 1.70 (0.94 – 3.09) | 0.70 (0.23 – 2.13) | 1.45 (0.75 – 2.81) | 1.24 (0.75 – 2.06) | 1.19 (0.63 – 2.23) |
| Cognitive Symptom: >2= mentions (c) | 1.16 (0.58 – 2.34) | 1.26 (0.63 – 2.53) | 0.88 (0.35 – 2.26) | 0.86 (0.44 – 1.66) | 0.98 (0.33 – 2.88) | 0.77 (0.37 – 1.64) | 0.61 (0.36 – 1.05) | 1.12 (0.58 – 2.13) |
| Affective Symptom: >2= mentions (c) | 0.51 (0.25 – 1.03) | 0.57 (0.29 – 1.12) | 0.93 (0.41 – 2.10) | 0.51 (0.30 – 0.86)^{**} | 0.48 (0.21 – 1.10) | 0.35 (0.19 – 0.66)^{**} | 0.82 (0.50 – 1.32) | 0.95 (0.53 – 1.68) |
| Somatic Symptom: >2= mentions (c) | 1.39 (0.71 – 2.74) | 1.01 (0.52 – 1.96) | 1.11 (0.49 – 2.48) | 0.66 (0.38 – 1.14) | 1.02 (0.47 – 2.42) | 1.18 (0.63 – 2.19) | 1.61 (1.01 – 2.56)^{**} | 0.70 (0.39 – 1.22) |
| Past Suicide Ideation: Yes (b) | 1.37 (0.75 – 2.50) | 1.03 (0.57 – 1.89) | 0.89 (0.40 – 1.98) | 0.80 (0.47 – 1.37) | 0.50 (0.19 – 1.34) | 0.92 (0.51 – 1.67) | 0.93 (0.59 – 1.46) | 0.84 (0.48 – 1.48) |
| Past Suicide Attempt: Yes (b) | 1.04 (0.51 – 2.11) | 1.51 (0.78 – 2.91) | 1.74 (0.76 – 4.00) | 1.35 (0.75 – 2.41) | 0.44 (0.12 – 1.64) | 2.06 (1.10 – 3.87)^{**} | 1.18 (0.71 – 1.95) | 1.19 (0.63 – 2.20) |

p-value: [‡] <0.05; ^{**} < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix

For peer review only

Table A1: Results from sensitivity analysis. Fully-adjusted multinomial logistic regression analysis investigating the association between demographic and clinical factors with different antidepressant treatments.

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|------------------------------|------------------------------|---------------------------|---------------------------|--------------------|---------------------------|---------------------------|---------------------------|
| Age | 1.04 (1.03 – 1.06) | 1.03 (1.02 – 1.04) | 0.97 (0.96 – 0.99) | 1.01 (1.00 – 1.02) | 1.01 (0.99 – 1.03) | 0.97 (0.96 – 0.98) | 1.03 (1.02 – 1.04) | 1.02 (1.01 – 1.04) |
| Gender (a) | 1.00 (0.60 – 1.67) | 1.32 (0.83 – 2.08) | 0.95 (0.56 – 1.61) | 0.96 (0.66 – 1.40) | 1.06 (0.58 – 2.00) | 1.04 (0.71 – 1.54) | 2.62 (1.89 – 3.64) | 1.15 (0.76 – 1.75) |
| Race (White) | 1.19 (0.71 – 2.01) | 0.95 (0.60 – 1.51) | 0.80 (0.50 – 1.30) | 1.12 (0.78 – 1.61) | 1.90 (0.98 – 3.74) | 1.23 (0.85 – 1.78) | 0.75 (0.54 – 1.04) | 1.34 (0.87 – 2.06) |
| Past Inpatient: Yes (b) | 1.13 (0.49 – 2.62) | 1.24 (0.58 – 2.65) | 0.97 (0.41 – 2.27) | 0.90 (0.43 – 1.90) | 0.60 (0.14 – 2.54) | 0.47 (0.21 – 1.05) | 0.71 (0.38 – 1.32) | 0.70 (0.31 – 1.51) |
| Past Benzodiazepine Use: Yes (b) | 1.39 (0.75 – 2.57) | 1.04 (0.56 – 1.93) | 1.63 (0.82 – 3.24) | 1.57 (0.92 – 2.67) | 1.78 (0.80 – 3.98) | 0.88 (0.48 – 1.60) | 1.62 (1.04 – 2.55) | 1.68 (0.98 – 2.89) |
| Past Mood Stabiliser Use: Yes (b) | 2.61 (1.15 – 5.91) | 1.22 (0.47 – 3.17) | 1.46 (0.50 – 4.30) | 0.96 (0.39 – 2.35) | 2.60 (0.93 – 7.21) | 1.53 (0.65 – 3.60) | 1.28 (0.62 – 2.63) | 3.08 (1.51 – 6.30) |
| Past Antidepressant Use: Yes (b) | 3.70 (1.55 – 8.86) | 1.06 (0.59 – 1.93) | 0.54 (0.30 – 0.98) | 0.73 (0.48 – 1.12) | 1.58 (0.72 – 3.46) | 1.28 (0.81 – 2.02) | 0.97 (0.63 – 1.48) | 1.23 (0.72 – 2.12) |
| Has had Psychotherapy treatment before: Yes (b) | 0.65 (0.31 – 1.37) | 0.90 (0.47 – 1.71) | 0.92 (0.44 – 1.94) | 0.52 (0.28 – 1.01) | 1.05 (0.43 – 2.57) | 0.88 (0.50 – 1.58) | 0.56 (0.33 – 0.96) | 0.77 (0.41 – 1.42) |
| Has been referred to IAPT services: Yes (b) | 1.80 (1.09 – 2.98) | 0.98 (0.63 – 1.54) | 0.81 (0.50 – 1.31) | 0.95 (0.68 – 1.36) | 1.10 (0.61 – 2.01) | 0.64 (0.45 – 0.93) | 0.87 (0.63 – 1.20) | 0.75 (0.50 – 1.13) |
| Psychotic Symptom: >=2 mentions (c) | 0.90 (0.45 – 1.81) | 1.57 (0.85 – 2.91) | 0.98 (0.49 – 1.96) | 1.54 (0.90 – 2.65) | 0.73 (0.27 – 2.02) | 1.39 (0.80 – 2.40) | 1.20 (0.75 – 1.87) | 1.24 (0.70 – 2.22) |
| Cognitive Symptom: >=2 mentions (c) | 1.35 (0.70 – 2.63) | 1.38 (0.73 – 2.61) | 1.17 (0.58 – 2.37) | 0.95 (0.52 – 1.72) | 0.95 (0.35 – 2.56) | 0.80 (0.42 – 1.49) | 0.71 (0.43 – 1.17) | 1.32 (0.73 – 2.40) |
| Affective Symptom: >=2 mentions (c) | 0.54 (0.28 – 1.04) | 0.60 (0.32 – 1.12) | 0.93 (0.47 – 1.83) | 0.58 (0.36 – 0.92) | 0.70 (0.33 – 1.51) | 0.42 (0.25 – 0.68) | 0.80 (0.51 – 1.25) | 0.92 (0.54 – 1.56) |
| Somatic Symptom: >=2 mentions (c) | 1.42 (0.74 – 2.71) | 1.02 (0.55 – 1.90) | 0.90 (0.47 – 1.75) | 0.66 (0.40 – 1.09) | 0.88 (0.40 – 1.96) | 1.09 (0.66 – 1.81) | 1.60 (1.04 – 2.46) | 0.71 (0.42 – 1.22) |
| Past Suicide Ideation: Yes (b) | 1.40 (0.79 – 2.47) | 1.11 (0.64 – 1.91) | 1.03 (0.57 – 1.86) | 0.80 (0.50 – 1.29) | 0.80 (0.36 – 1.79) | 0.84 (0.53 – 1.35) | 0.91 (0.61 – 1.37) | 0.82 (0.49 – 1.38) |
| Past Suicide Attempt: Yes (b) | 0.94 (0.49 – 1.83) | 1.46 (0.81 – 2.61) | 1.79 (0.97 – 3.29) | 1.26 (0.76 – 2.08) | 0.62 (0.23 – 1.64) | 1.56 (0.97 – 2.52) | 1.11 (0.71 – 1.74) | 1.12 (0.65 – 1.95) |

p-value: ‡ <0.05; †† < 0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

Table A2: Results from sensitivity analysis. Fully-adjusted multinomial logistic regression analysis investigating the association between demographic and clinical factors with different antidepressant treatments in the adult-only cohort (n = 1248).

| | Any one SNRI and Mirtazapine | Any one SSRI and Mirtazapine | Any two SSRIs | Citalopram | Escitalopram | Fluoxetine | Mirtazapine | Venlafaxine |
|---|------------------------------|------------------------------|---------------------------|---------------------------|--------------------|---------------------------|---------------------------|---------------------------|
| Age | 1.04 (1.02 – 1.05) | 1.03 (1.01 – 1.05) | 0.99 (0.97 – 1.02) | 1.00 (0.99 – 1.02) | 1.00 (0.99 – 1.03) | 0.99 (0.98 – 1.01) | 1.03 (1.01 – 1.04) | 1.02 (1.01 – 1.04) |
| Gender (a) | 0.88 (0.51 – 1.50) | 1.28 (0.79 – 2.08) | 0.89 (0.47 – 1.70) | 0.90 (0.50 – 1.36) | 1.02 (0.52 – 2.01) | 1.24 (0.78 – 2.00) | 2.33 (1.63 – 3.34) | 1.08 (0.69 – 1.70) |
| Past Inpatient: Yes (b) | 1.08 (0.44 – 2.62) | 0.96 (0.41 – 2.21) | 0.30 (0.07 – 1.26) | 0.79 (0.34 – 1.83) | 0.58 (0.10 – 3.22) | 0.51 (0.19 – 1.37) | 0.60 (0.30 – 1.20) | 0.59 (0.25 – 1.40) |
| Past Benzodiazepine Use: Yes (b) | 1.44 (0.76 – 2.75) | 1.26 (0.66 – 2.43) | 2.89 (1.30 – 6.43) | 1.56 (0.87 – 2.80) | 1.85 (0.79 – 4.35) | 1.14 (0.58 – 2.25) | 1.92 (1.18 – 3.12) | 1.87 (1.04 – 3.33) |
| Past Antipsychotic Use: Yes (b) | 2.01 (1.14 – 3.55) | 1.30 (0.73 – 2.27) | 1.03 (0.47 – 2.27) | 1.09 (0.66 – 1.81) | 1.67 (0.80 – 3.52) | 1.01 (0.57 – 1.80) | 1.14 (0.74 – 1.75) | 1.50 (0.90 – 2.50) |
| Past Mood Stabiliser Use: Yes (b) | 2.25 (0.96 – 5.26) | 1.02 (0.36 – 2.86) | 1.11 (0.30 – 4.22) | 0.77 (0.28 – 2.10) | 2.52 (0.87 – 7.29) | 1.71 (0.67 – 4.35) | 1.24 (0.58 – 2.64) | 2.65 (1.23 – 5.70) |
| Past Antidepressant Use: Yes (b) | 2.76 (1.12 – 6.81) | 0.92 (0.48 – 1.78) | 0.40 (0.19 – 0.85) | 0.70 (0.42 – 1.13) | 2.19 (0.85 – 5.67) | 1.04 (0.59 – 1.86) | 0.80 (0.50 – 1.30) | 1.08 (0.59 – 2.00) |
| Has been referred to IAPT services: Yes (b) | 2.04 (1.20 – 3.47) | 0.97 (0.60 – 1.59) | 0.91 (0.50 – 1.69) | 0.98 (0.66 – 0.47) | 1.34 (0.68 – 2.60) | 0.97 (0.61 – 1.53) | 0.93 (0.64 – 1.34) | 0.82 (0.52 – 1.28) |
| Psychotic Symptom: >=2 mentions (c) | 0.80 (0.38 – 1.67) | 1.70 (0.87 – 3.31) | 0.89 (0.34 – 2.21) | 1.67 (0.92 – 3.03) | 0.72 (0.23 – 2.18) | 1.45 (0.75 – 2.81) | 1.22 (0.74 – 2.03) | 1.18 (0.63 – 2.21) |
| Cognitive Symptom: >=2 mentions (c) | 1.14 (0.57 – 2.30) | 1.28 (0.65 – 2.56) | 0.89 (0.35 – 2.25) | 0.84 (0.43 – 1.62) | 0.99 (0.34 – 2.88) | 0.78 (0.37 – 1.64) | 0.60 (0.35 – 1.02) | 1.11 (0.58 – 2.11) |
| Affective Symptom: >=2 mentions (c) | 0.51 (0.25 – 1.01) | 0.59 (0.30 – 1.14) | 0.92 (0.41 – 2.08) | 0.49 (0.29 – 0.82) | 0.51 (0.23 – 1.15) | 0.36 (0.20 – 0.67) | 0.79 (0.53 – 1.28) | 0.93 (0.53 – 1.66) |
| Somatic Symptom: >=2 mentions (c) | 1.40 (0.72 – 2.75) | 0.99 (0.52 – 1.92) | 1.11 (0.50 – 2.50) | 0.66 (0.38 – 1.16) | 1.00 (0.42 – 2.36) | 1.17 (0.63 – 2.18) | 1.63 (1.02 – 2.59) | 0.69 (0.40 – 1.22) |
| Past Suicide Ideation: Yes (b) | 1.37 (0.76 – 2.48) | 1.08 (0.60 – 1.95) | 0.89 (0.40 – 1.98) | 0.79 (0.47 – 1.35) | 0.53 (0.20 – 1.39) | 0.92 (0.51 – 1.67) | 0.92 (0.60 – 1.44) | 0.84 (0.50 – 1.48) |
| Past Suicide Attempt: Yes (b) | 1.03 (0.51 – 2.09) | 1.44 (0.76 – 2.77) | 1.75 (0.77 – 4.00) | 1.45 (0.81 – 2.58) | 0.44 (0.12 – 1.62) | 2.06 (1.11 – 3.84) | 1.18 (0.72 – 1.95) | 1.17 (0.64 – 2.16) |

p-value: ‡ <0.05; †† <0.001

a – Reference: Female

b – Reference: No

c – Reference: 0 or 1 mention of the symptom. Individuals with zero or one mention of a symptom in the 12-month period prior to the observation frame were considered to be undergoing a milder experience of the symptom compared to individuals who had two or more mentions of the symptom in the 12-month period.

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

| | Item No. | STROBE items | Location in manuscript where items are reported | RECORD items | Location in manuscript where items are reported |
|---------------------------|----------|--|---|---|---|
| Title and abstract | | | | | |
| | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 2 | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | Page 2 |
| Introduction | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 4 | | |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 4 | | |
| Methods | | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | Page 2 | | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 5, 6 and 7 | | |
| Participants | 6 | (a) <i>Cohort study</i> - Give the eligibility criteria, and the | Page 5 | RECORD 6.1: The methods of study population selection (such as codes or | Page 5 - 8 |

| | | | | | | |
|---|------------------------------|---|--|--|---|------------|
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 | | <p>sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p> | | <p>algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p> | | |
| 26 27 28 29 30 31 32 | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Page 5- 8 | RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | Page 5 - 8 |
| 33 34 35 36 37 38 39 40 | Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 5 – 8 | | |
| 41 42 | Bias | 9 | Describe any efforts to address potential sources of bias | Page 5 | | |
| 43 44 45 46 47 | Study size | 10 | Explain how the study size was | Page 5 | | |

| | | | | |
|---|----------------------------------|------------|--|--|
| | | arrived at | | |
| 1 2 3 4 5 6 | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | |
| 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses | Page 7 |
| 31 32 33 34 35 36 37 38 39 40 41 | Data access and cleaning methods | | .. | RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. |
| 42 43 44 | Linkage | | .. | RECORD 12.3: State whether the study included person-level, institutional- |

Page 5

Page 5

| | | | | | |
|------------------|----|---|-----------------|--|--------|
| | | | | level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided. | |
| Results | | | | | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram | Page 8 | RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram. | Page 5 |
| Descriptive data | 14 | (a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount) | Page 8, 16 - 21 | | |
| Outcome data | 15 | <i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures | Page 16 - 21 | | |
| Main results | 16 | (a) Give unadjusted estimates | Page 16 - 21 | | |

| | | | | | |
|-------------------|----|---|---------|--|---------|
| | | and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | | | |
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Page 8 | | |
| Discussion | | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Page 10 | | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 10 | RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported. | Page 10 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Page 10 | | |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 11 | | |

| Other Information | | | | | |
|---|----|---|---------|--|----------------|
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 12 | | |
| Accessibility of protocol, raw data, and programming code | | .. | | RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code. | Not Applicable |

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.